High-Fat Diet Enhances Triglyceride Recycling, Impairs UCP1-Mediated Thermogenic Activity, and Causes Insulin Resistance in Rat Brown Adipocytes by Da Eira, Daniel Pereira
  
HIGH-FAT DIET ENHANCES TRIGLYCERIDE RECYCLING, IMPAIRS UCP1-
MEDIATED THERMOGENIC ACTIVITY, AND CAUSES INSULIN RESISTANCE IN RAT 
BROWN ADIPOCYTES  
 
DANIEL PEREIRA DA EIRA 
 
A THESIS SUBMITTED TO THE FACULTY OF GRADUATE STUDIES IN PARTIAL 
FULFILMENT OF THE REQUIREMENTS FOR THE DEGREE OF  
 
MASTER OF SCIENCE 
 
GRADUATE PROGRAM IN KINESIOLOGY AND HEALTH SCIENCE 
YORK UNIVERSITY  
TORONTO, ONTARIO 
 
JUNE 2019 
© DANIEL PEREIRA DA EIRA, 2019 
 
 
 
 
 
 
 
ii 
 
Abstract 
Brown adipose tissue (BAT) is rich in uncoupling protein 1 (UCP1) and dissipates energy 
through thermogenesis. However, even though BAT mass and its UCP1 content increase under 
conditions of diet-induced obesity (DIO), marked expansion of the WAT is not prevented, 
suggesting impairment of BAT-mediated diet-induced thermogenesis (DIT) in obesity. Thus, the 
objective of this study was to investigate the metabolic and molecular mechanisms that regulated 
BAT thermogenesis in DIO. To accomplish this, rats were fed a high-fat diet (HFD) for eight 
weeks. Subsequently, glucose and fat metabolism and the molecular mechanisms underlying these 
processes were assessed in BAT adipocytes. Despite increasing BAT mass (1.3-fold), UCP1 
content (2.1-fold), and isoproterenol (Iso)-induced lipolysis (1.6-fold), HFD reduced UCP1-
mediated glucose (62%) and fatty acid (57%) oxidation, and abrogated insulin-stimulated glucose 
uptake in BAT adipocytes. Furthermore, phosphoenolpyruvate carboxykinase (PEPCK) and 
glycerol kinase (GyK) contents, as well as glycerol and palmitate incorporation into lipids were 
all significantly increased (1.8-fold, 2.1-fold, 2-fold, and 1.7-fold, respectively) in HFD BAT. This 
coincided with 3.6- and 3.7-fold elevations in lipoprotein lipase (LPL) and cluster of differentiation 
36 (CD36), respectively, in HFD BAT adipocytes. Morphological analysis also revealed that these 
adipocytes were more unilocular in appearance. Altogether, these findings provide novel evidence 
that HFD suppresses UCP1-mediated thermogenesis, shifts metabolism toward triglyceride 
recycling, and induces insulin resistance in BAT adipocytes. These adaptive responses to chronic 
HFD are consistent with a mechanism that attenuates the contribution of BAT to DIT and favors 
the growth of adipose tissue and the development of obesity. Thus reversal of these adaptive 
metabolic responses of brown adipocytes to DIO could be of therapeutic value for obesity and its 
related metabolic disorders.
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1. Introduction 
 
Obesity is a global epidemic that is impacting adults and children alike1–3. Of growing 
concern are the several comorbidities that are associated with obesity, including Type II diabetes, 
cardiovascular disease, and certain types of cancer1,2. Besides being a major concern to public 
health, it is also a tremendous economic burden for the health care system1. The development of 
obesity is attributed to alterations in energy balance4, namely reduced energy expenditure and/or 
increased energy intake1. However, the macronutrient composition of a diet also plays a role in 
determining adiposity4. For example, a carbohydrate-rich diet increases glucose availability and 
triggers the release of insulin, which in turn suppresses lipolysis and enhances the storage of 
glucose in the liver and skeletal muscles, as well as of triglycerides (TG) in the adipose tissue4,5. 
The ensuing increase in adiposity, particularly in subcutaneous and visceral regions of the body, 
is what characterizes obesity6,7.  
Pharmacological strategies to reduce energy intake and combat obesity have been used, 
unfortunately this therapeutic approach has produced disappointing results with respect to weight 
loss and maintenance of a reduced body weight in the long term8. Furthermore, drugs that act on 
the central nervous system (CNS) to control appetite have numerous deleterious side effects, and 
end up being withdrawn from the market8,9. For instance, the serotonin agonists fenfluramine and 
dexfenfluramine were used to suppress appetite and facilitate long-term weight loss10. Due to non-
specific binding to serotonin receptor subtypes, these drugs also caused pulmonary hypertension 
and valvular heart disease10,11. Recently, lorcaserin, a more specifically acting serotonin-receptor 
agonist, was developed to avoid these adverse side-effects10. However, patients still report 
experiencing headaches, nausea, fatigue and constipation10.  To avoid the deleterious side effects, 
scientists have focused on the development of pharmacological strategies that enhance energy 
2 
 
expenditure without targeting the CNS. In this context, the molecular mechanisms that regulate 
energy storage and dissipation in fat cells has received great attention recently8. The intent is to 
alter adipose tissue function to promote energy dissipation and reduce fat storage, which could be 
very useful to combat obesity and its related metabolic disorders. It is now well established that 
two types of adipose tissues exist in humans:  white and brown. The former is essentially an energy 
storage compartment, whereas the latter is specialized in heat production. These two fat depots 
play a major role in energy metabolism in the body and have been extensively characterized with 
respect to their morphological and physiological features. BAT has sparked interest in the field of 
obesity and weight management for its energy dissipating properties. However, little is known 
regarding the effects of a high-fat diet on the molecular mechanisms that govern the metabolic 
capacity of BAT. In this context, this thesis aims to determine the implications of DIO for BAT 
function and metabolism. 
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2. Literature Review 
2.1. WHITE ADIPOSE TISSUE (WAT) 
 
2.1.1. Location and Structure 
The white adipose tissue (WAT) is found mainly in subcutaneous and visceral depots and, 
as previously mentioned, is specialized to store energy in the form of TG12. This tissue is primarily 
composed of adipocytes and stromal cells13. The developmental origin of the white adipocyte 
remains a controversial topic. However, a simplified model of adipocyte lineage suggests that 
white adipocytes arise mostly from myogenic factor 5 negative (Myf5-) cells14. Adipocytes vary 
in size, depending on the amount of TG that is stored in them12. Regardless, the white adipocyte 
contains a large lipid droplet (LD) that occupies ~90% of the cytoplasm and moves the nucleus 
and organelles, including mitochondria, to the periphery of the cell8,12,15. This confers a unilocular 
appearance to the cell. WAT mitochondria are sparse in number, more so in larger adipocytes, and 
display a long, elongated morphology, with randomly oriented cristae12.  
 
 
 
 
 
 
 
Figure 1: The unilocular white adipocyte. Microscopic image of the subcutaneous inguinal fat 
with hematoxylin and eosin (H&E) staining at 20x magnification (A)16. An illustration depicting 
the unilocular lipid droplet (LD) in the white adipocyte and its low mitochondrial content (B). N, 
nucleus. 
A 
B 
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Accordingly, white adipocytes exhibit limited oxidative capacity, promoting the ideal conditions 
for the storage of lipids17. In situations of increased energy demand, such as exercise or prolonged 
fasting, these lipids are mobilized by TG hydrolysis, also known as lipolysis, to meet the metabolic 
needs of peripheral tissues (e.g. skeletal muscles, heart, liver)12,15.  
2.1.2. Regulation of Lipolysis 
Lipid storage and lipolysis are tightly regulated by insulin and catecholamines in the fed and 
fasted-state, respectively13. Briefly, lipolysis is initiated by the binding of catecholamines to a β-
adrenergic receptor5. These receptors are coupled to stimulatory G-proteins that activate adenylyl 
cyclase (AC)18,19. AC subsequently increases the formation of cyclic AMP (cAMP), which 
continues the signaling cascade by activating protein kinase A (PKA)18. PKA then phosphorylates 
perilipin (PL), the protective covering on lipid droplets, causing it to change conformation and 
release adipose triglyceride lipase (ATGL)-activating comparative gene identification-58 (CGI-
58)5. Furthermore, the phosphorylation of perilipin causes fragmentation of the lipid droplet, 
increasing its surface area for contact with lipases20 and facilitates the interaction of hormone 
sensitive lipase (HSL) with the lipid droplet21. PKA also phosphorylates and activates hormone 
sensitive lipase (pHSL)18,22. Consequently, the complete hydrolysis of TG can occur, with ATGL 
hydrolyzing TG to diacylglycerol (DAG), phosphorylated HSL (pHSL) hydrolyzing DAG to 
monoacylglycerol (MAG) and monoacylglycerol lipase hydrolyzing MAG to a free-fatty acid 
(FFA) and glycerol molecule5. The release of FFA into the circulation allows for the transport of 
this substrate to energy-demanding tissues, which is particularly relevant during periods of 
exercise or fasting23.  
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Figure 2: The lipolytic signaling cascade. The release of NE from a sympathetic nerve binds to a 
β-receptor that is coupled to a stimulatory G-protein. The G-protein subsequently activates AC, 
which in turn promotes the formation of cAMP. cAMP then activates PKA which phosphorylates 
PL. PL phosphorylation enables the release of CGI-58, which then binds to and activates ATGL. 
PKA-mediated phosphorylation also activates HSL. Phosphorylation of PL initiates its 
dissociation from the lipid droplet, increasing the surface area available for ATGL and pHSL to 
perform lipolysis. ATGL, pHSL and MAGL hydrolyze TAG, DAG and MAG, respectively, 
releasing three FAs and a glycerol molecule.   
 
However, a portion of the FAs that are derived from lipolysis are used within the cell to 
fulfil other purposes24,25. For instance, 30-40% of FFAs are re-esterified to TAG, which is 
dependent on the intracellular production of glycerol-3-phosphate (G3P)24,25. A portion of the 
FFAs released from lipolysis also act as signaling molecules by interacting with a group of 
transcription factors known as peroxisome proliferator-activated receptors (PPARs)24,25. The four 
PPARs that exist are PPARα, PPARγ-1 and -2 and PPARδ24. These transcriptional regulators are 
activated by the binding of FAs24. From there they form heterodimers with other nuclear receptors 
and  interact with transcriptional coactivators, such as peroxisome proliferator-activated gamma 
coactivor-1α (PGC1α), to promote gene expression24. PPARα and PPARδ regulate the 
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transcription of genes that are involved in oxidative phosphorylation24. Conversely, PPARγ is 
highly expressed in WAT and regulates genes that promote lipid synthesis and storage24. In 
combination with CCAAT/enhancer binding protein (C/EBP), PPARγ has been identified as a 
crucial regulator for adipocyte differentiation26. Thus, lipolysis is an important mechanism that 
serves both metabolic and transcriptional functions.  
In diet-induced obesity (DIO), the dysregulation of lipolytic enzymes can generate lipid 
intermediates that are harmful to the cell27. Under such conditions, the activity of the DAG lipase, 
HSL, is reduced27. Consequently, incomplete lipolysis occurs, leading to the accumulation of the 
lipid intermediate DAG27, which has been linked to the development of insulin resistance (IR)20,28. 
Therefore, the regulation of lipolysis is of tremendous importance for the metabolic and 
transcriptional functioning of the adipocyte.  
2.1.3. Insulin-Mediated Lipid Storage 
Insulin is a hormone that is crucial for the regulation of glucose and fat metabolism29. It is 
released in response to elevated levels of glucose in the blood and promotes the uptake of glucose 
and FAs in several tissues5,6. Furthermore, insulin is a potent inhibitor of lipolysis, utilizing several 
mechanisms to interfere with the lipolytic signaling cascade5. Firstly, insulin-stimulation activates 
adipose-specific phospholipase A2 (AdPLA2), which increases the production of prostaglandin E2 
(PGE2), that, in turn, interferes with the function of AC and prevents the downstream activation of 
PKA5. Insulin-stimulation also results in the activation of AKT5. AKT serves several metabolic 
functions, however, in the context of lipolysis, it enhances the activation of phosphodiesterase, 
which suppresses cAMP production and, in turn, inhibits the activity  of PKA5. AKT also activates 
mammalian target of rapamycin complex-1 (mTORC1) which suppresses the expression of ATGL 
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transcripts and reduces the availability of lipolytic enzymes5. Finally, insulin promotes the 
transcription of FSP27, a lipid droplet protein that inhibits lipolysis5.  
In addition to inhibiting TG breakdown, insulin promotes the acute synthesis of TG by 
increasing the availability of intracellular glucose and FAs5. In the context of glucose, insulin 
enhances the translocation of glucose transporter 4 (GLUT4) to the membrane, providing a channel 
for glucose entry into the cell5. GLUT4 translocation begins with the binding of insulin to its 
receptor, leading to the phosphorylation of insulin receptor proteins (IRS) by tyrosine kinase29. 
IRS interact with and activate phosphatidylinositol 3-kinase (PI3K)29, leading to the production of 
phosphatidylinositol-3,4,5-triphosphate (PIP3)
29. PIP3 subsequently recruits phosphoinositide-
dependent kinase 1 (PDK1), mTORC1 and AKT5,29–31. Both PDK1 and mTORC1 phosphorylate 
and activate AKT29,31. Once activated, AKT promotes the translocation of GLUT4 to the plasma 
membrane by phosphorylating and deactivating AKT substrate 160 (AS160), which inhibits the 
exocytosis of the GLUT4 vesicle31. Glucose can thereafter be imported into the cell and be used 
for the production of G3P, which serves as the backbone for FA esterification and TG synthesis5. 
FA uptake is also increased by insulin-stimulation5. Insulin enhances lipoprotein lipase (LPL) 
activity on the capillary endothelial surface5,21 which breaks down lipoprotein TG into FAs and 
glycerol5. Circulating TG are derived from dietary fats and are packaged into chylomicrons or very 
low density lipoproteins (VLDL). The import of FAs is mediated by fatty acid transporter protein 
1 (FATP1) and cluster differentiation 36 (CD36) and permits the entry of the hydrolyzed substrates 
into the adipocyte, where they can be re-esterified into TG5,21. 
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Figure 3: Insulin stimulated glucose and fatty acid uptake in adipocytes. Insulin stimulation 
activates IRS, which binds to PI3K and enhances the production of PIP3. In turn, PIP3 recruits 
mTORC1 and PDK1 to phosphorylate and activate AKT. AKT then phosphorylates AS160, 
decreasing its inhibition on the GLUT4 vesicle and allowing it to translocate to the membrane. 
Membrane-bound GLUT4 increases glucose uptake into the cell, where it can be converted to G3P 
and used for FA esterification and TG synthesis. AKT also promotes TG formation by enhancing 
de novo fatty acid synthesis. Furthermore, insulin enhances fatty acid uptake into the cell by 
facilitating the activity of LPL and fatty acid transporters, including CD36. 
 
In addition to enhancing FA uptake, endogenous FA synthesis is also upregulated by AKT-
mediated signaling5. Activated AKT phosphorylates and inactivates AMP-activated protein kinase 
(pAMPK), leaving acetyl-CoA carboxylase (ACC) dephosphorylated and active, allowing it to 
increase FA synthesis5. In concert, these mechanisms provide the adipocyte with the necessary 
substrates for TG synthesis, promoting the storage of glucose and FAs in the cell5.  
 2.1.4. Hyperinsulinemia in DIO 
 
Hyperinsulinemia, or elevated levels of insulin in the circulation, is typical under 
conditions of chronic obesity and is a compensatory mechanism used to regulate hyperglycaemia6. 
However, as discussed previously, elevated levels of insulin promote the accumulation of lipids 
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and the development of adiposity6. In general, adipose tissue composes 20% and 30% of body 
mass in men and women, respectively20. These percentages can increase dramatically in obese 
individuals, reaching 50% in the more extreme cases20. The expansion of fat mass and the 
development of obesity precedes the infiltration of immune cells, which have been  suggested to 
contribute to the development of insulin resistance (IR)5. A relationship between macrophage 
content and adipocyte size in multiple fat depots has been reported32. Macrophages secrete several 
factors, known as cytokines, that are implicated in the pathophysiology of IR33. Tumor necrosis 
factor alpha (TNFα) is one such macrophage-derived cytokine33. In a murine model with a targeted 
null mutation of the TNFα gene, obese mice were more responsive to insulin and were better able 
to regulate blood glucose levels when subjected to a glucose tolerance test33. In addition to these 
systemic effects, tissue-specific adaptations were also observed. In obese TNFα-/- mice, tyrosine 
phosphorylation of the insulin receptor was increased in both fat and muscle, in comparison to the 
TNFα+/+ obese mice33. The authors also identified a reduction in circulating FFA in these animals, 
which they suggested could be the cause for the improved sensitivity to insulin33.  
In this context, adipose tissue carries tremendous impact for the development of insulin 
resistance and hyperglycemia. It is important to note that chronically elevated levels of glucose in 
the blood could potentially lead to the development of full-blown diabetes, where pancreatic β-
cell function is impaired6. Therefore, understanding the mechanisms that are implicated in lipolysis 
and lipogenesis under conditions of DIO are crucial for the management of obesity and must be 
considered for the treatment of related metabolic disorders.  
2.1.5. WAT as an Endocrine Organ 
 
WAT also performs endocrine functions by actively releasing adipocyte-derived cytokines, 
also referred to as adipokines34. Leptin, for example, is released in proportion to the quantity of 
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adipose tissue and signals to the hypothalamus to promote satiety35,36. When adipose tissue stores 
are low, leptin secretion is reduced and neuropeptide Y secretion is increased to promote hunger 
and food intake26. In the context of energy metabolism, leptin plays an important role in increasing 
sympathetic nervous system (SNS) activity and energy dissipation35. This was demonstrated in 
leptin-deficient mice that exhibited lower body temperatures and suppressed sympathetic nerve 
activity37 . Adiponectin is another adipocyte cytokine (adipokine) that is expressed in both WAT 
and BAT38. Unlike leptin, adiponectin release is reduced in obese, insulin resistant individuals 
either due to genetic factors that affect the expression of the adiponectin gene or lifestyle factors 
causing obesity, including diet38. Adiponectin has been shown to improve insulin sensitivity in 
insulin resistant models38 and plays a role in regulating cold-induced thermogenesis in the energy-
dissipating BAT39. 
In summary, WAT is a multi-functional tissue that fulfills several metabolic and endocrine 
functions. However, the accumulation of fat can lead to adverse consequences including the 
development of insulin resistance and diabetes. It is therefore important to consider DIO and its 
implications for energy storage in adipose tissue. 
2.2. BROWN ADIPOSE TISSUE (BAT) 
2.2.1. Origin, Location and Structure 
In rodents, BAT can be found in the axillary and interscapular regions12. Until recently, 
BAT was thought to only be relevant in human infants and small mammals for the purpose of 
thermoregulation40. However, recent studies have shown active BAT in human adults, sparking 
interest in this tissue as a potential therapeutic tool for the treatment of obesity40,41. BAT cells, or 
brown adipocytes, share a common origin with muscle cells, originating from myogenic-regulatory 
factor 5-expressing cells (Myf5+)42. The proliferation of BAT preadipocytes is regulated by NE 
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and its stimulation of the β1-cAMP pathway18. When treated with NE, brown preadipocytes 
increase their formation of cAMP, leading to the activation of PKA43. In turn, PKA activation 
increases the expression of ribonucleotide reductase43, an enzyme that performs the limiting step 
for DNA synthesis and cell proliferation18. NE also promotes the differentiation of brown 
adipocytes through a cAMP/PKA/cAMP response element binding protein (CREB) pathway. In 
this pathway, NE binds to β3-AdR, increasing the formation of cAMP and, in turn, the activation 
of PKA18. Thereafter, PKA phosphorylates CREB, which promotes the expression of enzymes and 
other transcription factors, including PGC1α, that contribute to the differentiation of these 
thermogenic cells18,42. Contrary to white adipocytes, brown adipocytes contain several lipid 
droplets (multilocular appearance) and are relatively smaller in diameter; 15-50 μm12. These 
adipocytes are also abundant in mitochondria that are spherical with laminar cristae12. The elevated 
mitochondrial content in this tissue is what gives it its brown appearance15. These mitochondria 
are also characteristically rich in uncoupling protein 1 (UCP1), which uncouples electron transport 
from adenosine triphosphate (ATP) production, resulting in the production of heat, also known as 
thermogenesis15,42.  
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 4: The multilocular brown adipocyte. Microscopic image of iBAT with hematoxylin and 
eosin (H&E) staining at 40x magnification (A). An illustration depicting the multilocular 
appearance of the brown adipocyte and its high mitochondrial content (B). N, nucleus. 
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2.2.2. Glucose and Fatty Acid Metabolism: Glycolysis, β-Oxidation and the TCA 
Cycle  
UCP1-mediated thermogenesis uncouples the oxidation of glucose and FAs from the 
production of ATP40,44,45. In the context of glucose, once it is imported into the cell, it can be 
diverted to glycolysis45. The glycolytic pathway starts with the ATP-consuming phosphorylation 
of glucose by hexokinase45. Although this seems counterintuitive to the objective of energy 
production, the early consumption of ATP in glycolysis is considered an important investment for 
the latter stages of ATP synthesis46. Phosphoglucose isomerase subsequently converts Glucose-6-
phosphate (G6P) into fructose-6-phosphate (F6P), which is, in turn, phosphorylated by 
phosphofructokinase-1 (PFK-1) to produce fructose-1,6,-diphosphate (F-1,6-diP)45. Aldolase then 
breaks this molecule into two three-carbon compounds, glyceraldehyde-3-phosphate and 
dihydroxyacetone phosphate (DHAP)45. However, DHAP can also be converted to 
glyceraldehyde-3-phosphate by phosphotriose isomerase, providing the glycolytic pathway with a 
second energy producing molecule45,46. The glyceraldehyde-3-phosphate molecules are 
subsequently processed by glyceraldehyde-3-phosophate dehydrogenase (GAPDH) for the 
production of two 1,3-diphosphoglycerate molecules45. This step involves the reduction of NAD+ 
to NADH and the phosphorylation of glyceraldehyde-3-phosphate with an inorganic phosphate47. 
Phosphoglycerate kinase then catalyzes the conversion of 1,3-diphosphoglycerate to 3-
phosphoglycerate, phosphorylating an ADP molecule to produce ATP in the process45. 3-
phosphoglycerate is then converted to 2-phosphoglycerate and phosphoenolpyruvate (PEP), in 
sequence, by phosphoglycerate mutase and enolase, respectively45.  
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Fig. 5: The glycolytic pathway. Glucose is phosphorylated by to form glucose-6-phosphate (G6P), 
which in turn is converted to fructose-6-phosphate and phosphorylated again by 
phosphofructokinase-1 (PFK-1). Fructose-1,6-diphosphate is then broken into dihydroxyacetone 
phosphate (DHAP) and glyceraldehyde-3-phosphate. However DHAP can also be converted to 
glyceraldehyde-3-phosphate by phosphotriose isomerase. Glyceraldehyde-3-phosophate 
dehydrogenase (GAPDH) then converts glyceraldehyde-3-phosphate to 1,3-diphosphoglycerate, 
reducing NAD+ to NADH in the process. Subsequently, 1,3-diphosphoglycerate is converted to 3-
phosphoglycerate by phosphoglycerate kinase, resulting in the first production of an ATP molecule 
in the glycolytic pathway. From there, 3-phosphoglycerate is processed into 2-phosphoglycerate 
by phosphoglycerate mutase. Subsequently, enolase catalyzes the conversion of 2-
phosphoglycerate to phosphoenolpyruvate (PEP). Finally, PEP is used by pyruvate kinase to 
phosphorylate a second ADP and produce pyruvate. Pyruvate can then be used for lactate 
production or it can be converted into Acetyl-CoA. The conversion of pyruvate to lactate is 
reversible. 
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Finally, pyruvate kinase phosphorylates a second ADP molecule, converting phosphoenolpyruvate 
to pyruvate and concluding glycolysis45. In total, this process involves the synthesis of four ATP 
molecules and the breakdown of two, resulting in the net production of two ATP molecules47. 
Pyruvate can thereafter be reversibly converted to lactate by lactate dehydrogenase (LDH)46,48, or 
it can be transported into the mitochondria and decarboxylated by pyruvate dehydrogenase (PDH) 
to form acetyl-CoA48.  
If pyruvate is converted to Acetyl-CoA, it can enter the Tricarboxylic Acid (TCA) Cycle, 
which is important for the production of metabolic substrates that drive the ETC49. The first step 
of the TCA Cycle is the condensation of Acetyl-CoA with oxaloacetate, which is mediated by the 
enzyme citrate synthase to produce citrate50. Aconitase then converts citrate to isocitrate which 
serves as a precursor for α-ketoglutarate formation50. The decarboxylation of isocitrate to α-
ketoglutarate is catalyzed by isocitrate dehydrogenase and produces a molecule of CO2
50. More 
importantly, this step leads to the reduction of NAD+ to NADH, which is an important reducing 
equivalent for the production of ATP in the ETC50,51. Subsequently, α-ketoglutarate is converted 
to succinyl-CoA by α-ketoglutarate dehydrogenase, which, in parallel, produces the second CO2 
and NADH molecules in the TCA Cycle50,51. Succinyl-CoA is thereafter converted to succinate by 
succinic thiokinase50. This step is also marked by the phosphorylation of GDP to GTP50.  Succinate 
dehydrogenase then converts succinate to fumarate50. In parallel, FAD is reduced to FADH2, which 
is also important for the function of the ETC50. The following step involves the hydration of a 
double bond in fumarate that is catalyzed by fumarase, resulting in the production of malate50. 
From here, malate dehydrogenase regenerates an oxaloacetate molecule from malate and produces 
NADH2
50. Oxaloacetate can then re-enter the TCA cycle by interacting with another acetyl-CoA 
and initiating the aforementioned sequence of events50. 
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The initial stages of FA metabolism is different from that of glucose; however, both 
converge at the TCA Cycle. FAs enter the cell and are esterified to Coenzyme A (CoA) to make 
Acyl-CoA. The transport of the FA into the mitochondria is dependent on a carnitine shuttle, which 
is composed of carnitine palmitoyltransferase I (CPT1), carnitine/acylcarnitine translocase 
(CACT) and carnitine palmitoyltransferase II (CPTII)44. The first step of mitochondrial fatty acid 
import involves the CPT1-mediated conversion of Acyl-CoA to acylcarnitine44. This step is rate-
limiting for the oxidation of FAs in the mitochondria44. Following this, CACT facilitates the import 
of acylcarnitine through the inner mitochondrial membrane and into the matrix44. Finally, CPTII 
re-esterifies acylcarnitine to Acyl-CoA, releasing the carnitine and preparing the FA for 
oxidation44. Once inside the mitochondria, Acyl-CoA undergoes β-oxidation, which is the splitting 
of the Acyl-CoA into two carbon Acetyl-CoAs44. β-oxidation requires the action of four enzymes 
in sequence44. The first stage of β-oxidation is catalyzed by acyl-CoA dehydrogenases, of which 
there are also four; short-chain acyl-CoA dehydrogenase, medium-chain acyl-CoA 
dehydrogenase, long-chain acyl-CoA dehydrogenase and very long-chain acyl-CoA 
dehydrogenase44,52. As their names imply, they act on fatty acid chains of varying lengths and 
convert acyl-CoA to 2-Enoyl-CoA52. 2-Enoyl-CoA is converted to 3-hydroxyacyl-CoA by 2-
Enoyl-CoA hydratase52. 3-hydroxyacyl-CoA dehydrogenase is the third enzyme involved in β-
oxidation and its function is to convert 3-hydroxyacyl-CoA to 3-oxoacyl-CoA52. The final step of 
β-oxidation is the cleavage of 3-oxoacyl-CoA to acetyl-CoA and a saturated acyl-CoA52. This final 
step is catalyzed by 3-oxoacyl-CoA thiolase52. The residual acyl-CoA undergoes additional rounds 
of β-oxidation for the continuous generation of Acetyl-CoA52. Once formed, Acetyl-CoA enters 
the TCA Cycle to drive the production of the metabolic equivalents required for oxidative 
phosphorylation; NADH and FADH2
50,51,53. 
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2.2.3. Glucose and FA Metabolism: Electron Transport Chain (ETC), Oxidative 
Phosphorylation and Mitochondrial Uncoupling 
The oxidation of glucose and fatty acids in the TCA Cycle generates the reducing agents 
NADH and FADH2
53, both of which drive oxidative phosphorylation in the ETC49. NADH 
dehydrogenase and succinate dehydrogenase receive electrons from NADH and FADH2, 
respectively53. These electrons are passed onto Coenzyme Q which acts as a mobile transporter for 
these electrons to the next ETC complex53. The electrons are shuttled to complex III, cytochrome 
c and cytochrome c oxidase, in sequence53. Finally, the electrons are used to reduced O2 to H2O
54. 
As these electrons are transported across the complexes, protons are pumped into the 
intermembrane space of the mitochondria54. Pumping occurs at Complexes I, III, and IV and leads 
to the formation of a proton gradient between the intermembrane space and the mitochondrial 
matrix40,55. This electrochemical gradient is dissipated as the protons enter the matrix through the 
ATP synthase complex in a process that leads to the generation of ATP40,55. However, if UCP1 is 
present and active, protons have an alternative entry into the mitochondrial matrix without going 
through ATP Synthase56. The re-entry of protons into the matrix that occurs independently of ATP 
Synthase, is known as proton leak, or State 4 respiration, and uncouples electron transport from 
ATP synthesis57, releasing the substrate-derived chemical energy as heat40.  
2.2.4. Thermogenesis is Regulated by SNS Activity 
In BAT, UCP1-mediated thermogenesis is induced by activation of the SNS18. BAT is 
highly innervated and rich in β3-AdR18. As previously mentioned, the stimulation of these 
receptors by NE initiates a lipolytic signaling cascade that activates the hydrolytic enzymes ATGL 
and HSL18. The hydrolysis of TG in brown adipocytes increases intracellular FFAs that serve to 
activate UCP119. The long chain fatty acid (LCFA)-shuttling model has been proposed to explain 
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how UCP1 is activated in brown adipocytes. In this model, LCFAs interact through their 
hydrophobic tails to UCP1 and bind protons, whereby a conformational change in UCP1 ensues, 
translocating the LCFA and proton to the mitochondrial matrix58. The hydrophobic tail of the 
LCFA does not allow it to dissociate from UCP158, thus, after the proton is released into the matrix, 
the LCFA is returned to the opposite side of the inner mitochondrial membrane, where it can 
facilitate the translocation of another proton58.  
2.2.5. An Alternative Fate for Glucose and FAs in the BAT 
However, as described earlier, not all FAs derived from lipolysis enter the mitochondria 
for oxidation or mitochondrial uncoupling. Many FFA return to WAT and BAT to be re-esterified 
into TAG59. This means that a constant source of G3P is required in these tissues60. Glycerol is 
derived from the lipolysis of TG, glycolysis or glyceroneogenesis59,60. Firstly, following complete 
lipolysis, or the hydrolysis of the three FAs that are esterified to a glycerol backbone, glycerol is 
released and can be used for re-esterification59. Contrary to WAT, BAT possesses Glycerol Kinase 
(GyK), allowing it to phosphorylate the free glycerol and use it for TAG re-synthesis59,60. The 
second source of glycerol is glycolysis. In the fed-state, BAT increases its uptake of glucose from 
the ciruclation61,62 and favors  the storage of TG within its adipocytes59. Insulin-stimulation 
increases glucose uptake and glycolysis, which enhance the production of ATP and 3-
phosphoglycerol59,60. Both of these products are required for FA esterification; 3-phosphoglycerol 
is the backbone for TAG synthesis and ATP is required for esterification to take place59. In BAT, 
much of the available glycerol for TG synthesis is made in a process known as glyceroneogenesis, 
which is driven by phosphoenolpyruvate carboxykinase (PEPCK)60. The expression of PEPCK is 
regulated by several transcription factors, including PPARγ59. PEPCK-mediated conversion of 
oxaloacetate to phosphoenolpyruvate is the defining step for classical glyceroneogenesis60. 
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Interestingly, in BAT, PEPCK activity is disproportionately high relative to the amount of glycerol 
being produced60. This can be attributed to the fact that in BAT is used for the dual purpose of 
fueling de novo glycerol production and to replenish Citric Acid Cycle intermediates that are 
required to maintain high rates of TG breakdown/re-esterification and oxidation60. Mottilo et al. 
investigated glyceroneogenesis and lipid turnover in BAT and WAT and found that lipolysis and 
TG re-synthesis are linked17. In fact, knocking out ATGL eliminated β3 adrenoreceptor-specific 
enhancement in glycerol incorporation into TG and mitochondrial respiration, and decreased 
PEPCK protein content in brown adipocytes17. This led the researchers to propose a possible fatty 
acid cycling mechanism within BAT, as well as a relationship between TG synthesis, lipolysis and 
oxidation17.  
2.2.6. Cold and Exercise-Mediated Regulation of BAT Function 
The SNS-induced activation of UCP1 is of tremendous physiological importance in the context 
of cold tolerance and thermogenesis18. The first response to acute cold-exposure is shivering, 
where heat is generated by ATP-consuming muscular contractions56. Following prolonged cold-
exposure, shivering subsides and is replaced by non-shivering thermogenesis18,56. The distribution 
of the produced heat to the periphery is facilitated by the extensive vascularization of BAT42. The 
heat-generating capacity of BAT is suggested to be an evolutionary mechanism to cope with cold-
stress in hibernating animals and in humans18. The cold-induced activation of BAT has received 
great attention for its therapeutic potential in the management of obesity. Sepa-Kishi et al. used a 
rat model of cold-acclimation and showed that although cold-exposed animals ate more, they had 
significant reductions in Sc Ing and Epid fat masses16. 
The cold-induced activation of BAT also plays a broader role in the context of circulating 
metabolic substrates63. BAT effectively accelerates the clearance of dietary TG and glucose from 
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the circulation63 and oxidizes fat to a greater extent16. This was demonstrated by Sepa-Kishi et al.  
in isolated BAT adipocytes, where they measured basal and oligomycin (Oligo)-induced palmitate 
oxidatiion16. Both basal and Oligo-induced palmitate oxidation were enhanced to a similar degree 
in the BAT of cold-acclimated animals16. They also found no significant difference between basal 
and Oligo-induced oxidation in the brown adipocytes of the cold-exposed animals leading them to 
conclude that mitochondrial uncoupling accounted for much of the FA oxidation occurring in 
brown fat16. Interestingly, BAT adipocytes enlarge with cold-exposure due to TAG storage16. 
Although this may seem contradictory to the notion of thermogenesis, it is a mechanism used by 
the adipocytes to provide the thermogenic machinery with readily available substrate16. The cold-
induced activation of BAT is met with the recruitment of brown-like cells in WAT, known as beige 
adipocytes, that exhibit similar metabolic and morphological characteristics23.   
2.2.7. Beige Fat: Recruitment and Activation of Remote BAT 
Beige fat arises from WAT in a process known as “browning”23,64.  This conversion occurs in 
adipocytes that are subject to specific stimuli, including cold and β-adrenergic stimulation40,65 and 
is more common in the subcutaneous fat where the adipocytes exhibit greater plasticity to 
“brown”23. Cold-exposure triggers morphological and molecular adaptations in these adipocytes, 
causing them to become more multilocular and abundant in UCP1, although not to the same extent 
as brown adipocytes65. Interestingly, these adipocytes do not rely on mitochondrial uncoupling to 
the same extent as BAT for thermogenesis16. Instead, thermogenesis is achieved through an 
energy-consuming phenomenon where TGs undergo a hydrolysis/re-esterification cycle16.  
 The browning of WAT is also promoted by exercise64. This was observed by Wu et al. in 
the Sc Ing fat of treadmill exercised rats. It is important to note that the Sc Ing fat depot did not 
adapt homogenously. Rather the adipocytes located centrally in the tissue possessed a greater 
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capacity to adapt thermogenic properties64. The site-specific differences in this tissue grants it 
metabolic flexibility whereby the peripheral areas can store TG and the centralized portion of the 
tissue can dissipate this stored energy23. Similar to cold-exposure the thermogenic adipocytes in 
this fat pad become more multilocular in appearance with endurance training, express higher levels 
UCP1 and PGC1α protein contents, and oxidized palmitate to a greater extent64. Interestingly, 
exercise exerted antagonistic effects on the BAT64. UCP1 content and PGC1α content was 
decreased in the BAT of exercised animals, relative to the control animals64. Furthermore, the 
oxidative capacity of BAT was decreased and adipocytes hypertrophied64. The explanation for this 
antagonistic regulation is that exercise, in itself, is thermogenic. Therefore, non-shivering 
thermogenesis from BAT is not required for thermoregulation and thus the tissue becomes less 
active64. Instead, the recruitment of beige fat is adapted as a compensatory reserve for 
thermogenesis, moving energy-dissipation away from core areas of the body23,64. Wu et al. also 
assessed the effects of diet on exercise-induced browning64. HF-feeding led to an enlargement in 
the area of Sc Ing adipocytes and drastically reduced UCP1 content64. Exercise reversed these 
effects, allowing the WAT adipocytes to display a similar morphology to that of the exercising 
low-fat fed animals. However, these outcomes did not significantly enhance the palmitate 
oxidation in the Sc Ing fat of the HF fed, exercising group relative to their sedentary counterparts64.  
Similar to exercise, diet was also regulated differently by the BAT64. In fact, HF-sedentary animals 
had significantly higher UCP1 and PGC1α contents as well as palmitate oxidation64. In this 
context, BAT plays a tremendous role in the regulation of energy balance64.  This process is also 
known as diet-induced thermogenesis64. 
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Because of the increase in energy expenditure, the activation and recruitment of thermogenic 
BAT has been widely proposed as a therapeutic tool for the treatment of obesity and insulin-
resistance23,63. 
2.2.8. Diet-Induced Thermogenesis 
As described previously, UCP1-mediated thermogenesis is not limited to thermoregulation and 
cold tolerance. Similar thermogenic mechanisms play an important role in the regulation of energy 
balance in diet-induced obesity (DIO)66. After a single meal, several circulating messengers travel 
to the brain to increase sympathetic stimulation to BAT18. These signals consist of insulin and 
glucose, as well as cholecystokinin, which is released from the stomach during a meal, and 
enterostatin, a pentapeptide that is released following the activation of pancreatic lipase18. These 
signals act on several hypothalamic nuclei, including the ventromedial nucleus (VMN) which was 
the first to be discovered and plays a crucial role in activating BAT67. The VMN has steroidogenic-
factor 1 neurons projecting to autonomic centers that sympathetically activate BAT67. VMN also 
increases BAT thermogenesis through its stimulation of other hypothalamic areas that regulate 
autonomic output67. In DIO, the dorsomedial nucleus (DMN) of the hypothalamus is crucial for 
energy homeostasis and the activation of BAT thermogenesis37. Leptin is released from WAT35,36 
as an indication of fat storage in the body, and stimulates leptin receptors in the DMN to regulate 
sympathetic outflow through the raphe pallidus to the BAT37. This mechanism serves to counter 
the development of obesity18. Therefore, beyond thermoregulation, BAT is also highly influential 
in the regulation of energy balance under conditions of energy surplus68. This was demonstrated 
by Feldman and colleagues who studied the effects of UCP1-ablation on DIT68. They found that 
the expected increase in weight in mice on the obesogenic diet was even more pronounced in the 
absence of UCP168. Surprisingly, UCP1-ablation led to the development of obesity in the standard 
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chow (SC) fed animals as well68. The researchers attributed this dramatic increase in mass to the 
enhanced metabolic efficiency of these UCP1-ablated mice68. Metabolic inefficiency is caused by 
diet-induced thermogenesis, or the increase in oxygen consumption due to the improved sensitivity 
to adrenergic stimulation in BAT68. UCP1-ablation eliminated DIT and, thus, the  metabolic 
inefficiency in the HF fed mice68. In contrast, the HF fed, wild-type mice displayed an accelerated 
thermogenic response68. The enhanced metabolic response in these mice was met by a four-fold 
increase in UCP1 content relative to the wild-type controls68. Thus, these researches posited that 
norepinephrine-stimulated, diet-induced thermogenesis is largely dependent on UCP1 activity68.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6: Schematic representation of leptin-stimulated diet-induced thermogenesis (DIT). The diet-
induced growth of adipose tissue is accompanied by an increase in leptin release from white-
adipose tissue (WAT). Leptin binds to receptors in the hypothalamus, stimulating sympathetic 
output to the brown adipose tissue (BAT). At the level of the BAT, lipolysis is initiated, releasing 
free fatty acids (FFA) that bind to and activate UCP1 and thermogenesis. This mechanism counters 
the continued growth of WAT by compensating for the diet-induced disruption in energy balance. 
Leptin also reduces appetite to decrease food intake and attenuate fat accumulation. N, nucleus. 
 
2.2.9. Chronic Obesity and Implications for BAT 
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The literature indicates that DIT is not sustainable under conditions of chronic HF-feeding, as 
we see in DIO69. This is compatible with the persistent growth in WAT mass seen in individuals 
on a high-fat diet (HFD)69. So et al. found that HF-feeding in rats caused a transient increase in 
heat production and whole-body energy expenditure that is sustained for two weeks69. Thereafter, 
heat production and energy expenditure was not different from that of control animals, and lead to 
a shift in energy balance that allows fat mass to grow69. In addition, these researchers found that 
ambulatory activity decreased gradually in the HF animals after the first two weeks of the diet, 
counteracting the initial burst in energy expenditure69. The authors suggested that the reduction in 
energy expenditure could, in part, be explained by the development of leptin resistance69. Leptin 
is released proportionally to WAT and is highly influential in the regulation of energy intake and 
non-exercise activity thermogenesis (NEAT)69. Accordingly, the HF animals had elevated plasma 
leptin, which is indicative of leptin resistance69. The reduction in energy expenditure, ambulatory 
activity and the consumption of a HFD combine to promote the growth of WAT and the 
progression of obesity69.  
At the level of the BAT, obesity also impacts energy dissipation41. Leitner et al demonstrated 
this by assessing BAT volume and metabolic activity in lean and obese subjects41. Following five 
hours of cold exposure, the subjects were injected with F-labelled fluorodeoxyglucose (F-FDG) 
and scanned using positron emission tomography/computed tomography (PET/CT) to determine 
the volume of six BAT depots and the glucose uptake occurring in each41.  They found that obese 
subjects have a higher volume of BAT relative to the lean subjects. Interestingly, the obese subjects 
still activated less BAT than the healthy participants41, which further reinforces the notion of DIO 
having a negative effect on the energy dissipating mechanisms of BAT.  
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The obesity-induced reduction in BAT function is also known as “whitening” of the brown fat, 
whereby BAT adapts the structural and functional characteristics of WAT70. Under conditions of 
obesity, it has been suggested that the dysfunction of BAT is initiated by the development of 
vascular rarefaction70. Brown adipocytes are typically highly vascularized for the reception of 
oxygen and nutrients and the delivery of heat to the rest of the body42. In fact, browning is 
characterized by increased vascularization of adipose tissue71. However, under conditions of DIO, 
high levels of intracellular fatty acids inhibit β-adrenergic signaling, which is crucial for the 
expression of vascular endothelial growth factor (VEGF)70. Consequently, the reduction in VEGF 
leads to a decrease in capillary density and the development of hypoxia70.  What ensues is an 
increase in mitochondrial dysfunction, reactive oxygen species (ROS) production and 
mitochondrial membrane depolarization which, in turn, promotes the cellular removal of these 
organelles in a process known as mitophagy70. The loss of UCP1-containing mitochondria 
facilitates the deposition of lipids in these cells and the development of a more unilocular 
appearance70. In combination, these morphological and molecular adaptations are what facilitate 
the “whitening” of the brown adipocytes70. Shimizu et al. studied diet-induced “whitening” of 
BAT by examining brown adipocyte function in animals consuming a high-fat, high-sucrose diet. 
They observed reductions in Ucp1 and Pgc1α transcript expression levels in these animals that 
was accompanied by a reduction in BAT vascularization71. In VEGF knock-out (KO) animals, 
they found that the resulting hypoxia led to reductions in β1- and β3-AdR content and suppressed 
PKA-mediated lipolysis71. Furthermore, the BAT mitochondria from these animals produced more 
ROS and displayed markers of mitophagy to a greater extent71. At the whole-body level, glucose 
and thermogenesis were impaired71.  In this context, DIO-induced reduction of VEGF stimulates 
hypoxia in the BAT, which precedes whitening and mitochondrial dysfunction71. 
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Although the aforementioned studies idenitified the diet-induced dysfunction of BAT, the 
molecular details underlying BAT-mediated mitochondrial uncoupling in DIO are still largely 
unknown. Leitner et al. used glucose uptake as a measure of BAT activity but did not consider 
heat production or DIT in their subjects. Furthermore, Shimizu et al. studied the effects of hypoxia 
on whitening and β-adrenergic signaling in BAT but did not assess whether this was having an 
impact on FA oxidation within the brown adipocytes. They also observed whole-body insulin 
resistance but did not investigate insulin-mediated glucose uptake in the BAT itself. Therefore, the 
purpose of our study is to measure FA and glucose oxidation in BAT under conditions of DIO to 
determine whether DIT is active. This will provide insight into potential oxidative mechanisms 
that are implicated under conditions of DIO and whether the tissue shifts its metabolism to 
preferentially oxidize glucose or FAs.  This study will also investigate how BAT handles the excess 
substrate that is available under conditions of DIO and will provide novel insights into the 
lipogenic and lipolytic activity of this tissue in an obesogenic model. Understanding the implicated 
metabolic pathways is of tremendous importance for addressing the implicated molecular 
mechanisms in BAT-mediated DIT and carries great potential for the therapeutic management of 
obesity and related metabolic disorders. 
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3. Rationale, Objectives & Hypotheses 
Based on previously published studies in animals64,69 and humans41,72, it is evident that BAT 
function is significantly altered under conditions of DIO. There is evidence of tissue enlargement 
and increased UCP1 content in BAT under DIO conditions in rats64,69 and that UCP1 ablation 
abolishes diet-induced thermogenesis (DIT) and causes obesity in mice living at 
thermoneutrality68. In fact, it has also been proposed that BAT enhances its thermogenic activity 
when food is abundantly available73,74. Such adaptive mechanism would operate to limit weight 
gain and maintain body weight relatively stable over time. However, despite evidence of BAT 
enlargement and increased UCP1 content, great expansion of adiposity still occurs in DIO64,69. 
Furthermore, it has been reported that cold-induced BAT recruitment is much lower in obese than 
lean humans41. In this context, the contribution of BAT to DIT and its ability to prevent the 
development of obesity under conditions of chronic energy surplus remain controversial. 
Additionally, the physiological and molecular mechanisms by which DIO regulates BAT 
thermogenesis are still poorly understood. 
 
Therefore, the objectives of this study are threefold: 
1. To determine if UCP1-mediated mitochondrial uncoupling is indeed enhanced to promote 
thermogenesis under conditions of energy surplus and DIO.  
2. To determine if DIO affects the ability of brown adipocytes to utilize glucose and fatty 
acids for thermogenesis. 
3. To investigate the molecular and metabolic mechanisms underlying the adaptive 
thermogenic responses of BAT to DIO. 
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I hypothesize that: 
1. DIO enhances glucose and fatty acid oxidation in BAT adipocytes due to increased UCP1-
mediated uncoupled respiration. 
2. DIO up-regulates the molecular machinery involved in the regulation of glucose and fatty 
acid uptake to increase the supply of substrate for thermogenesis. 
3. The molecular machinery involved in TG recycling (lipolysis/re-esterification) is enhanced 
due to increased substrate influx into BAT adipocytes and high thermogenic demand in 
DIO.  
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Abstract 
Brown adipose tissue (BAT) is rich in uncoupling protein 1 (UCP1) and dissipates energy 
through thermogenesis. However, even though BAT mass and its UCP1 content increase under 
conditions of diet-induced obesity (DIO), marked expansion of the WAT is not prevented, 
suggesting impairment of BAT-mediated diet-induced thermogenesis (DIT) in obesity. Thus, the 
objective of this study was to investigate the metabolic and molecular mechanisms that regulated 
BAT thermogenesis in DIO. To accomplish this, rats were fed a high-fat diet (HFD) for eight 
weeks. Subsequently, glucose and fat metabolism and the molecular mechanisms underlying these 
processes were assessed in BAT adipocytes. Despite increasing BAT mass (1.3-fold), UCP1 
content (2.1-fold), and isoproterenol (Iso)-induced lipolysis (1.6-fold), HFD reduced UCP1-
mediated glucose (62%) and fatty acid (57%) oxidation, and abrogated insulin-stimulated glucose 
uptake in BAT adipocytes. Furthermore, phosphoenolpyruvate carboxykinase (PEPCK) and 
glycerol kinase (GyK) contents, as well as glycerol and palmitate incorporation into lipids were 
all significantly increased (1.8-fold, 2.1-fold, 2-fold, and 1.7-fold, respectively) in HFD BAT. This 
coincided with 3.6- and 3.7-fold elevations in lipoprotein lipase (LPL) and cluster of differentiation 
36 (CD36), respectively, in HFD BAT adipocytes. Morphological analysis also revealed that these 
adipocytes were more unilocular in appearance. Altogether, these findings provide novel evidence 
that HFD suppresses UCP1-mediated thermogenesis, shifts metabolism toward triglyceride 
recycling, and induces insulin resistance in BAT adipocytes. These adaptive responses to chronic 
HFD are consistent with a mechanism that attenuates the contribution of BAT to DIT and favors 
the development of obesity and its related metabolic disorders. 
 
Key words: Diet-induced thermogenesis, obesity, mitochondria uncoupling, glucose oxidation, 
PEPCK, PGC1α.  
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Introduction 
Obesity is a rapidly growing global epidemic that is associated with several comorbidities 
including cardiovascular disease, cancer and Type II diabetes1,2. Besides being a major concern to 
public health, obesity also poses a great economic burden for the health care system1. In this 
context, research has focused on developing strategies to combat the development of obesity. 
Recently, adipose tissue and its ability to store and dissipate energy has sparked great interest as a 
potential therapeutic tool for the management of obesity and related metabolic disorders. In 
general, there are two main forms of adipose tissue: white and brown. White adipose tissue (WAT) 
is highly specialized to store fatty acids and glucose as triglycerides (TG) and release it under 
conditions of energy demand12,23. The adipocytes that compose this tissue are unilocular in 
appearance, with a large lipid droplet occupying the majority of the volume of the cell12. The 
second form of adipose tissue is brown adipose tissue (BAT). Brown adipocytes are typically 
multilocular in appearance with several small lipid droplets12,23. Unlike WAT, this tissue is also 
rich in mitochondria that contain uncoupling protein-1 (UCP1), which uncouples electron transport 
from oxidative phosphorylation resulting in the production of heat in a process known as 
thermogenesis18.  
The activation of BAT UCP1 has been studied classically under conditions of cold-
exposure. Cold-exposure activates the sympathetic nervous system (SNS) and the release of 
norepinephrine (NE) in BAT18. The binding of NE to beta-adrenergic receptors on the brown 
adipocytes initiates lipolysis within the cells and increases the release of fatty acids (FAs) from 
intracellular TG18. The binding of these FAs to UCP1 is what promotes mitochondrial uncoupling 
and thermogenesis in BAT18,58. Cold-induced activation of BAT has produced promising results 
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for the management of obesity16. In fact, Sepa-Kishi et al. showed that cold-acclimation reduced 
WAT mass in rats despite an increase in food intake16. 
 Interestingly, BAT can also be activated under conditions of diet-induced obesity (DIO) 
where the stimulus is a WAT-derived hormone known as leptin35,36. Similar to cold-exposure, 
leptin enhances sympathetic nerve activity, lipolysis and UCP1-mediated thermogenesis in BAT37. 
In this context, the dissipation of energy is known as diet-induced thermogenesis (DIT) and serves 
to maintain energy homeostasis within the organism and prevent the growth of adipose tissue18..  
 However, based on previously published studies in animals64,69 and humans41,72, it is 
evident that BAT function is significantly altered under conditions of DIO. There is evidence of 
tissue enlargement and increased UCP1 content in BAT under DIO conditions in rats64,69 and that 
UCP1 ablation abolishes diet-induced thermogenesis (DIT) and causes obesity in mice living at 
thermoneutrality68. In fact, it has also been proposed that BAT enhances its thermogenic activity 
when food is abundantly available73,74. Such adaptive mechanism would operate to limit weight 
gain and maintain body weight relatively stable over time. However, despite evidence of BAT 
enlargement and increased UCP1 content, great expansion of adiposity still occurs in DIO64,69. 
Furthermore, it has been reported that cold-induced BAT recruitment is much lower in obese than 
lean humans41. In this context, the contribution of BAT to DIT and its ability to prevent the 
development of obesity under conditions of chronic energy surplus remain controversial. 
Additionally, the physiological and molecular mechanisms by which DIO regulates BAT 
thermogenesis are still poorly understood. Therefore, the objective of this study was to investigate 
the molecular and metabolic mechanisms that regulate BAT DIT under conditions of DIO. We 
hypothesized that DIO would increase DIT due to enhanced UCP1-mediated mitochondrial 
uncoupling. To address this, we fed rats a high-fat diet (HFD) for eight weeks. Subsequently, 
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glucose and fat metabolism and the molecular mechanisms underlying these processes were 
assessed in isolated BAT adipocytes. Here, we show that although there was an increase in UCP1 
content, HFD suppressed BAT DIT, increased TG recycling and caused insulin resistance in rat 
brown adipocytes. 
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Materials and Methods 
Reagents –– Type II collagenase, isoproterenol, FA-free bovine serum albumin (BSA), palmitic 
acid, and the free glycerol determination kit was purchased from Sigma (St. Louis, MO, USA). 
Oligomycin was purchased from Cayman Chemical (Ann Arbor, MI, USA). [1-14C] palmitic acid 
and [14C(U)] glycerol and D-[U-14C] glucose were purchased from American Radiolabeled 
Chemicals (St. Louis, MO, USA). The lactate assay kit was from BioVision (Milpitas, CA). 
Protease (cOmplete Ultra Tablets) and phosphatase (PhosSTOP) inhibitors were obtained from 
Roche Diagnostics GmbH (Mannheim, Germany). The β-actin (Cat # 4067), tyrosine hydroxylase 
(TH; cat. no. 2792), adipose triglyceride lipase (ATGL; cat. no. 2138), hormone-sensitive lipase 
(HSL; cat. no. 4107), and pHSLSer660 (cat. no. 4126) antibodies were purchased from Cell Signaling 
(Danvers, MA, USA). The β3-adrenergic receptor (β3-AdR, Cat # sc-50436) and Glucose 
transporter type 4 (GLUT4, Cat # sc-7938) antibodies were purchased from Santa Cruz 
Biotechnology (Dallas, TX, USA). The carnitine palmitoyltransferase 1B (CPT1B, Cat # PB9491) 
antibody was purchased from BosterBio (Pleasanton, CA, USA). Glucose transporter type 1 
(GLUT1, Cat # ab115730), glycerol kinase (GYK) (Cat # ab180525), phosphoenolpyruvate 
carboxykinase cytoplasmic (PEPCK-C, Cat # ab28455), and UCP1 (Cat # ab23841) were 
purchased from Abcam (Toronto, ON, Canada). The peroxisome proliferator-activated receptor 
gamma coactivator-1α (PGC-1α, Cat # AB3242) antibody was purchased from Millipore 
(Temecula, CA, USA).  
Animals and diet – Male albino rats (Wistar strain) at approximately 250g were housed at 22°C on 
a 12/12-h light/dark cycle. These rats were assigned to either a standard laboratory chow (SC) diet 
(27% protein, 13% fat and 60% carbohydrates from Lab Diet Cat #5012) group or a high-fat (HF) 
diet (20% protein, 60% fat, 20% carbohydrates from Research Diets, Cat # D12492) group and 
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were fed ad libitum for 8 weeks. After 8 weeks of feeding, animals were anesthetized and tissues 
were harvested for experiments. The protocol containing all animal procedures described in this 
proposal were specifically approved by the Committee on the Ethics of Animal Experiments of 
York University (York University Animal Care Committee, YUACC, permit number 2016-5) and 
performed strictly in accordance with the YUACC guidelines. All surgeries were performed under 
ketamine/xylazine anesthesia, and all efforts were made to minimize suffering. 
Adipose tissue morphology - Morphological analysis of iBAT was performed using light 
microscopy as described previously64,75. Briefly, a sample (~50–100 mg) of each fat tissue was 
collected and fixed in 4% paraformaldehyde, 0.1 M phosphate-buffered saline (PBS), pH 7.4, for 
24h at room temperature. Following fixation, adipose tissue samples were washed three times in 
PBS and stored at 4°C in 70% ethanol. Samples were then embedded in paraffin blocks, sectioned, 
and stained with hematoxylin and eosin (H & E). Digital images of tissue sections were captured 
with a Nikon Eclipse Ti (Nikon Canada, Mississauga, ON, Canada) under X20 and X40 
magnification. 
Body weight and fat mass – Changes in body weight were measured by comparing weekly weight 
recordings to a baseline measurement. Interscapular brown adipose tissue (iBAT), aortic BAT 
(aBAT), subcutaneous inguinal (Sc Ing), and epididymal (Epid) fat pads were extracted, trimmed 
of any non-fat tissue, and individually weighed. 
Brown adipose tissue extraction and adipocyte isolation – iBAT and aBAT were extracted and 
carefully trimmed of any muscle, connective tissue, and white fat and used for adipocyte isolation 
as previously described76. iBAT and aBAT were combined to maximize the yield of brown 
adipocytes. The tissues were initially incubated in Krebs-Ringer bicarbonate HEPES buffer 
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(KRBH) prepared fresh on the day of each experiment from stock solutions of salts and buffers 
(stored at 4°C) to give the following final concentrations: 120 mM NaCl, 4.8 mM KCl, 2.5 mM 
CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 15 mM NaHCO3, 30 mM HEPES, and type II 
collagenase (0.83 mg/ml). The tissues were incubated at 37°C under orbital agitation (120 orbital 
strokes/min) for 5 min. Subsequently, the combined tissues were vortexed for 5s and filtered, with 
the filtrate being discarded. The remaining tissues were finely minced and incubated in fresh 
KRBH-4% BSA containing collagenase (0.83 mg/ml) at 37°C under orbital agitation (120 orbital 
strokes/min) for about 20 – 30 min. The digested tissue was then strained using a nylon mesh and 
isolated cells were transferred to plastic tubes, washed 3 times, and resuspended in KRBH 
containing 3.5% FA free BSA (KRBH-3.5% BSA). In order to distribute an equal number of 
adipocytes in each treatment condition, cell diameters were measured and total cell counts were 
determined77. 
Glucose and palmitate oxidation – Glucose and palmitate oxidation as a measure of oxidative 
capacity were assessed by 14CO2 release in isolated BAT adipocytes (5x10
5 cells) as previously 
described75. Adipocytes were incubated in KRBH-3.5% BSA containing either 0.2 μCi/ml of [1-
14C] palmitic acid and 200 μM non-labelled palmitate, or 0.2 μCi/ml of D-[U-14C] glucose and 5.5 
mM non-labeled D-glucose for 1h. To examine the effect of lipolysis on substrate oxidation, the 
β-agonist isoproterenol (Iso, 100 nM) was added to the media. To distinguish substrate oxidation 
for ATP production (coupled respiration) from UCP1-mediated proton leak (uncoupled 
respiration), the ATP Synthase inhibitor oligomycin (Oligo) was added to cells 15 min prior to the 
incubation without or with Iso. Following the 1h incubation period, the media were acidified using 
0.2 ml of H2SO4 (5N) and kept sealed for one additional hour for the release and collection of 
14CO2 from the cells and media. The incubation vials were prepared with a centered well containing 
37 
 
a filter paper that was moistened with 0.2 ml of 2-phenylethylamine/methanol (1:1, vol:vol) for 
the capture of 14CO2. At the end of the incubation, the filter paper was removed from the well and 
placed in scintillation fluid for radioactive counting27,78. 
Lipolysis – Lipolysis was measured in isolated BAT adipocytes (7.5x105 cells) either under basal 
or Iso-stimulated (100 nM) conditions. Each assay was conducted in triplicates and samples were 
incubated for 75 min at 37°C with gentle shaking (50 orbital strokes/min). Following the 
incubation, a 200 μl aliquot of the incubation medium was extracted from each vial for the 
determination of glycerol concentration.  
Glycerol and Palmitate incorporation into lipids – Glycerol and Palmitate incorporation into lipids 
were measured using isolated BAT adipocytes (5x105 cells). Adipocytes were incubated in KRBH-
3.5% BSA containing 0.2 μCi/ml of [14C(U)] glycerol for 1h. Subsequently, lipid extraction took 
place according to the method of Dole and Meinertz79 and counted for radioactivity78. Palmitate 
incorporation into lipids was measured in isolated BAT adipocytes (5x105 cells) incubated in 
KRBH-3.5% BSA containing 0.2 μCi/ml of [1-14C] palmitic acid and 200 μM non-labelled 
palmitate for 1h. Lipids were extracted from these adipocytes using the Folch’s method80, dried 
under nitrogen, and resuspended in 50 µl of chloroform:methanol (2:1, v:v). Four µl of sample and 
TG standard (triolein, Nu-chek Prep Inc., Minnesota, USA) were spotted 2 cm above the lower 
edge of silica coated flexible polyester thin layer chromatography plates (20 cm x 20 cm) 
(Whatman, Maidstone, United Kingdom). Lipids were separated using a hexane–diethyl ether–
acetic acid (70:30:1, v:v:v) solvent and then exposed to iodine vapor for visualization. After the 
evaporation of iodine, the spots adjacent to the standard, corresponding to TG, were scraped off 
the plate and counted for radioactivity. 
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Glucose Uptake – Isolated adipocytes were used to determine glucose uptake as described 
previously81. Briefly, adipocytes were resuspended in glucose-free KRB containing HEPES (30 
mM; KRB-HEPES) and 1% BSA, pH 7.4. Subsequently, 4x105 cells were transferred to plastic 
tubes and incubated at 37°C for 1h. Insulin (100 nM) was added for the final 20 min of the 
incubation period. Subsequently, KRB-HEPES containing 0.5 mM 2-deoxy-D-glucose and 0.5 
μCi of 2-[1,2-3H]deoxy-D-glucose was added to the cells for 3 min, and the incubations were 
terminated by the addition of cytochalasin B (1.5 mM stock solution). Aliquots of cell suspension 
(240 μl) were quickly placed in plastic microtubes containing 100 μl of di-“isononyl” phthalate. 
The tubes were centrifuged for 30s (6000 × g) to separate cells from the radioactive incubation 
medium. Subsequently, fat cells were collected by cutting the tubes through the oil phase and 
transferred to scintillation vials to be counted for radioactivity. Nonspecific transport was 
determined in the same conditions, except that cytochalasin B (50 μM final concentration) was 
added to the medium before the addition of cells. Nonspecific values were subtracted from all 
conditions. 
Measurement of Lactate Production – Lactate production was measured using a commercially-
available kit as per the manufacturer’s instructions. Briefly, cells were isolated as previously 
described and incubated in KRBH-3.5% BSA for 75 min. Following incubation, an aliquot of 
media was extracted and stored at -80°C until analysis. 
RNA isolation and quantitative PCR – BAT samples were flash frozen in liquid nitrogen and stored 
at -80°C until RNA isolation. RNA was then isolated using TRIzolTM (ThermoFisher Scientific, 
Waltham, MA, USA) and resuspended in sterile water. Complimentary DNA (cDNA) was made 
with 2 μg of RNA using ABM EasyScriptTM Reverse Transcriptase cDNA Synthesis kit (Diamed, 
Mississauga, ON, Canada) as per the manufacturer’s instructions. All primers that were used for 
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real- time PCR have been previously designed using the software PrimerQuest (IDT) based on 
probe sequences available at the Affymetrix database (NetAffx™ Analysis Centre, 
http://www.affymetrix.com/ analysis) for each given gene. Samples were run in duplicates on a 
96-well plate. Each 20 μl reaction will contain 4 μl of cDNA, 0.4 μl of primer, 10 μl of Brightgreen 
2x qPCR Mastermix (Diamed, Mississauga, ON, Canada) and 5.6 μl of RNA-free water. qPCR 
analysis was performed using a Bio-Rad CFX96 Real Time PCR Detection System (Bio-Rad, 
Mississauga, ON, Canada) using the following amplification conditions: 95°C (10 min); 40 cycles 
of 95°C (15 s), 65°C (1 min); a 0.5°C step-wise increment from 65°C to 95°C. All genes were 
normalized to the housekeeping-gene β-actin, and relative differences in gene expression between 
treatment groups were determined using the ΔΔCt method82. Values are presented as fold increases 
relative to the SC group. The primers to be used are as follows: Cluster of differentiation (Cd36) 
forward (ACGACTGCAGGTCAACATACTGGT), reverse 
(TGGTCCCAGTCTCATTTGCCACA); lipoprotein lipase (Lpl) forward 
(TTGAGAAAGGGCTCTGCCTGAGTT), reverse (TGCTTCTCTTGGCTCTGACCTTGT). 
Western blotting – BAT samples were extracted from each rat, snap frozen in liquid nitrogen, and 
frozen at -80oC for later use. Tissues were homogenized in buffer containing 25 mM Tris-HCl, 25 
mM NaCl (pH 7.4), 1 mM MgCl2, 2.7 mM KCl, 1% Triton-X and protease and phosphatase 
inhibitors (Roche Diagnostics GmbH, Mannheim, Germany). Following centrifugation of the 
homogenates, the infranatant was collected. An aliquot of each sample was used in a Bradford 
assay to determine protein concentration. The samples were then diluted 1:1 with 2x Laemli 
sample buffer and incubated at 95°C for 5 min. Twenty-five μg of protein from each sample was 
loaded on to gels and subject to SDS-PAGE, transferred to a PVDF membrane, and probed with 
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the antibody of interest. The antibody dilutions were 1:1000 and the loading control was β-actin. 
Densitometry analysis was conducted using the Scion Image program. 
Statistical Analysis – Statistical analyses were conducted by using either unpaired t-tests or 
ANOVAs with the Bonferroni post-hoc comparison using the GraphPad Prism statistical analysis 
program. Statistical significance was set at p<0.05. Error bars are ±SEM. 
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Results 
Effects of HF-feeding on body weight and fat mass – In order to confirm that the HFD was causing 
obesity in the animals, we measured weight gain relative to baseline and adipose tissue mass. The 
weight gained in weeks 1 – 3 was not statistically significantly different between the two groups, 
although the average weight gained in the HFD group was higher in each of these weeks. After 
week 4, the weight gained in the HFD group was significantly higher than in the SC animals (188.6 
g ± 8.2 vs. 127.8 g ± 12.3 respectively) (Fig. 7A). This difference in weight gain persisted until the 
end of the study. After the eighth and final week of feeding, the weight gained by the HFD group 
was 1.5-fold higher than in the SC animals. Interestingly, the differences in weight gained in weeks 
five to six and six to seven in the SC animals were not statistically significant. In contrast, the HFD 
animals demonstrated persistent increments in weight gain throughout the entire study. This 
suggests that the stagnation in weight gain that the control animals experienced was overcome in 
the HFD group. Differences in weight gain can be attributed to the enhanced growth of WAT in 
the HFD animals. There was a 2-fold increase in the Sc Ing fat and a 2.4-fold increase in the Epid 
fat of the HFD animals (Fig. 7B). Interestingly, the growth of WAT was accompanied by an 
increase in BAT mass. iBAT and aBAT masses were increased 1.3- and 1.4-fold, respectively, in 
the HFD animals (Fig. 7C).  
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Fig. 7: Weight gain was significantly enhanced in the HF animals in weeks 4-8 of the diet (A). 
The difference in weight gain is likely attributable to the diet-induced increase in subcutaneous 
inguinal (Sc Ing) and epididymal (Epid) fat masses (B). This was met by an increase in iBAT and 
aBAT masses (C). *p<0.05 vs. SC. Repeated measures two-way ANOVA was used to compare 
groups/time, except for fat mass where a t-test was used. n = 10-17 rats. 
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Effects of HF-feeding on PGC1α, CPT1B and UCP1 contents: After observing an increase in BAT 
mass, it was important to determine whether this was accompanied by an increase in thermogenic 
machinery. Animals in the HFD group exhibited a 1.6-fold increase in PGC1α protein content 
(Fig. 8A), a 17.5-fold increase in CPT1B content (Fig. 8B) and a 2.1-fold increase in UCP1 
content, relative to the control group (Fig. 8C). Taken together, these results suggest that the 
molecular machinery necessary for oxidation and thermogenesis were enhanced in BAT under 
conditions of DIO. 
 
Effects of oligomycin and Iso on palmitate oxidation in the BAT of HF-fed animals- We then 
wanted to determine whether the increased expression of thermogenic proteins was altering 
substrate oxidation. Palmitate oxidation was measured as an indication of thermogenic capacity in 
the BAT. We measured this under four conditions: Basal, Iso, Oligo and Iso+Oligo. Under basal 
conditions, palmitate oxidation did not differ between the SC group and the HF group (Fig. 8D). 
Incubation with Oligo significantly increased palmitate oxidation 2.7-fold in the BAT of the SC 
animals but did not alter oxidation in the BAT of the HF animals (Fig. 8D). From these findings, 
we concluded that mitochondrial uncoupling accounts for the majority, if not all, of the palmitate 
being oxidized in the BAT of standard chow (SC)-fed control animals. However, when we 
compare SC and HFD groups, the difference in Oligo-induced palmitate oxidation is striking. In 
fact, palmitate oxidation was 57% lower in BAT adipocytes from HFD animals than controls (Fig. 
8D). Furthermore, when incubated with both Iso and Oligo, palmitate oxidation was reduced by 
44% in the brown adipocytes of the HF group (Fig. 8D), although this was not statistically 
significant. Thus, we clearly demonstrated an impairment in UCP1-mediated palmitate oxidation 
under conditions of HF-feeding. Interestingly, Iso-stimulated palmitate oxidation in the BAT of 
SC animals, in the absence or presence of Oligo, is significantly lower than palmitate oxidation 
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with Oligo alone (Fig. 8D), which suggests that Iso is having a suppressive effect on palmitate 
oxidation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8: HF-feeding increased PGC1α, CPT1B and UCP1 contents in the iBAT (A, B and C, 
respectively). However, the increased expression of thermogenic proteins did not elicit an 
enhanced thermogenic response. There was no significant difference in basal or isoproterenol 
(Iso)-stimulated palmitate oxidation between the SC and HF groups. Iso-stimulated palmitate 
oxidation seemed to be suppressed in the HFD animals in the absence or presence of Oligo. 
Furthermore, HF-feeding significantly reduced oligomycin (Oligo)-induced palmitate oxidation 
(D). A.U., arbitrary units. *p<0.05 vs. SC.  #p<0.05 vs. HF Oligo, SC Basal, SC Iso, SC Iso+Oligo. 
Two-way ANOVA was used to compare groups/conditions except for PGC1α, CPT1B and UCP1 
contents where t-tests were used. n = 4-15 rats for A-C. n = 10-14 rats for D. 
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Effects of HFD on Lpl and CD36 gene expression in BAT:  We considered that FA uptake could 
be a limiting factor for palmitate oxidation in the BAT of the HFD animals. As an indication of 
the adipocytes’ FA import capacity, we measured gene expression for FA uptake machinery. Lpl 
(Fig. 9A) and Cd36 (Fig. 9B) gene expressions were enhanced 3.6- and 3.7-fold in the BAT of the 
HF animals, respectively. These findings suggest that FA import is enhanced, rather than impaired, 
under conditions of HF-feeding and that an alternative mechanism is contributing to the reduction 
in palmitate oxidation. 
 
 
 
 
 
 
 
 
 
Fig. 9: HF-feeding increased Lpl and Cd36 gene expressions in the BAT (A and B, respectively). 
*p<0.05 vs. SC. T-tests were used to compare groups. n= 10-11 rats. 
 
Effects of oligomycin and Iso on glucose oxidation in the BAT of HF-fed animals- HF-feeding 
suppressed glucose oxidation in the BAT (Fig. 10). Basal glucose oxidation was reduced 48% in 
the BAT of the HF animals (Fig. 10). Similarly, Iso-stimulated glucose oxidation decreased 49 and 
56% in the HF group in the absence and presence of Oligo, respectively (Fig 10). Relative to basal 
measures, incubation with Oligo did not reduce glucose oxidation (Fig. 10), which suggests that 
0
1
2
3
4
5
SC HF
m
R
N
A
 E
x
p
re
s
s
io
n
 
(f
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 S
C
)
Cd36
0
1
2
3
4
5
SC HF
m
R
N
A
 E
x
p
re
s
s
io
n
 
(f
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 S
C
)
Lpl
A B 
* 
* 
46 
 
mitochondrial uncoupling accounts for the majority of the glucose being oxidized in both groups. 
However, our data show that mitochondrial uncoupling was impaired under conditions of DIO. 
Oligo-induced glucose oxidation was 62% lower in the BAT of the HF animals (Fig. 10), relative 
to the SC animals, indicating that there is a suppression in UCP1-mediated glucose oxidation under 
conditions of DIO.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10: HF-feeding impaired glucose oxidation and significantly reduced Oligo-induced glucose 
oxidation in BAT adipocytes. *p<0.05 vs. SC. Two-way ANOVA was used to compare 
groups/conditions. n = 10-14 rats. 
 
Effects of HF-feeding on GLUT1 and GLUT4 protein contents and glucose uptake in isolated 
brown adipocytes – HFD increased GLUT1 protein content ~25-fold but did not alter GLUT4 
content in iBAT (Fig. 11A and 11B, respectively). Importantly, the measure of GLUT4 content 
did not differentiate between cytosolic and membrane-bound forms of the protein. Therefore, we 
could not assess if HFD impaired GLUT4 translocation in iBAT adipocytes. However, we did 
measure glucose uptake in isolated iBAT adipocytes to assess whether HFD impaired the ability 
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of these cells to transport glucose under basal and insulin-stimulate conditions. We found that basal 
glucose uptake did not differ between HFD and SC animals. However, in the presence of insulin, 
SC adipocytes displayed a 2-fold increase in glucose uptake, whereas the HFD adipocytes did not 
respond to the hormone at all (Fig. 11C). In fact, insulin-stimulated glucose uptake was severely 
impaired in the BAT of HFD animals, revealing a 78% reduction relative to the SC group. In 
conclusion, BAT developed insulin resistance (IR) under DIO conditions. 
 
Effects of HFD on lactate production in isolated brown adipocytes – Lactate production was 
measured in isolated adipocytes under basal conditions. The HFD animals produced 2.7-fold more 
lactate than the SC animals. This result suggests that BAT metabolism shifted to glycolysis under 
conditions of DIO (Fig. 11D). 
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Fig. 11: HF-feeding increased GLUT1 protein content but did not change GLUT4 protein content 
(A and B, respectively). Under basal conditions, glucose uptake was comparable between the SC 
and HFD groups (C). However, BAT insulin-stimulated glucose uptake was shown to be 
significantly impaired with HF-feeding (C).  Lactate production was enhanced in BAT under 
conditions of DIO (D). *p<0.05 vs. SC. #p<0.05 vs. SC Basal, HF Insulin. t-tests were used to 
compare groups except for glucose uptake (C) where a Two-way ANOVA was used to compare 
groups/conditions. n = 4-5 for A-B. n = 5-9 for C-D. 
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Effects of a HFD on glycerol and palmitate incorporation into TAG and PEPCK and GyK content 
in brown adipocytes – HFD enhanced glycerol and palmitate incorporation into lipids 2- (Fig. 12C) 
and 1.7-fold (Fig. 12D), respectively in the BAT. This was supported by a 1.8-fold increase in 
PEPCK protein content (Fig. 12A) and a 2.1-fold increase in GyK protein content (Fig. 12B). In 
concert, these mechanisms favored the synthesis of TG. 
 
Effect of a HFD on adipocyte morphology – Under control conditions, brown adipocytes are 
multilocular in appearance (Fig. 13A). Following the consumption of a HFD, these adipocytes 
undergo morphological adaptations where they become more unilocular in appearance (Fig. 13B). 
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Fig. 12: HF-feeding increased PEPCK (A) and GyK (B) contents in the BAT. This was 
accompanied by an increase in glycerol and palmitate incorporation into TAG (C and D, 
respectively). *p<0.05 vs. SC. t-tests were used to compare groups. N = 8–15 rats for A–B. n = 6–
9 rats for C-D. 
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Fig. 13: Microscopic image of iBAT using H&E staining. Viewed at 40x magnification. In the SC 
animals, the brown adipocytes were more multilocular in appearance. HFD induced a 
morphological adaptation in these adipocytes, making them appear more unilocular.  
 
Effects of HF-feeding on lipolysis and β3-AdR, TyHy, ATGL and pHSL contents in the BAT – Basal 
lipolysis was reduced by 70% in the BAT of HF animals relative to the SC group, although the 
difference was not statistically significant (Fig. 14A). Western blot analysis revealed 84 and 27% 
reductions in Tyrosine hydroxylase (TyHy) and ATGL contents, respectively (Fig. 14B and 14D, 
respectively). HSL660 phosphorylation was increased under conditions of HF-feeding, although 
this was not statistically significant (Fig. 14E). Under Iso-stimulated conditions, lipolysis was 
enhanced 1.6-fold in the BAT of the HF animals (Fig. 14A). This was supported by the 6.1-fold 
increase in β3-AdR content in this group (Fig. 14C).   
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Fig. 14: HFD enhanced Iso-stimulated lipolysis but did not alter basal lipolysis (A). Accordingly, 
TyHy content was reduced in the BAT of HF-fed animals (B). This was compensated for by an 
increase in β3-AdR content (C). Furthermore, ATGL content was reduced and pHSL was unaltered 
in the BAT of HF animals (D and E, respectively). *p<0.05 vs. SC. ‡p<0.05 vs. SC Basal. #p<0.05 
vs. HF Basal, SC Iso. t-tests were used to compare groups except for Lipolysis (A) where a Two-
way ANOVA was used to compare groups/conditions. n = 6-8 for A. n = 4-5 rats for B-E. 
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Discussion 
Our study provides novel evidence indicating that the recruitment of BAT mass and 
thermogenic proteins is insufficient to increase mitochondrial uncoupling and DIT under 
conditions of chronic obesity. Instead, UCP1-mediated thermogenesis is impaired and BAT 
develops the functional and morphological characteristics of WAT. 
We were surprised to find that both palmitate and glucose oxidation were impaired with 
HF-feeding. As mentioned previously, we studied substrate oxidation in brown adipocytes under 
four conditions: Basal, Iso, Oligo and Iso+Oligo. Basal palmitate oxidation was not different 
between the two groups. Interestingly, we observed a marked difference in palmitate oxidation 
following an incubation of our cells with the ATP Synthase inhibitor, Oligo. As expected, Oligo-
induced palmitate oxidation was not significantly different from basal oxidation. This is because 
mitochondrial uncoupling accounts for the majority of the palmitate being oxidized in BAT16. 
However, despite the increase in UCP1 content in the BAT of the HF animals, Oligo-induced 
palmitate oxidation was significantly lower in comparison to what was seen in the SC animals. In 
this context, we can conclude that mitochondrial uncoupling is impaired under conditions of DIO. 
Thus, our original hypothesis is rejected. A possible explanation for this is that lipolysis is severely 
impaired, limiting the activation of UCP1 in the BAT18. In accordance with our hypothesis, we 
demonstrated decreases in TyHy and ATGL protein contents. These molecular adaptations likely 
originate from the diminishing sympathetic output from the hypothalamus as a result of diet-
induced leptin resistance69. When we stimulated the cells with an exogenous β-agonist (Iso), we 
observed an enhanced lipolytic response in the BAT of the HF animals. This was supported by a 
6.1-fold increase in β3-AdR protein content. The overexpression of β3-AdR is likely a 
54 
 
compensatory mechanism employed by the cell to maximize adrenergic activation, although, in 
vivo, it is futile given the impaired production of NE.  
Surprisingly, Iso-stimulation did not produce the expected increase in palmitate oxidation. 
In theory, the increased expression of CPT1B in the BAT of the HF animals should have facilitated 
the import of lipolysis-derived FAs into the mitochondria34, which is known to promote the 
activation of UCP1 and FA oxidation16,18. A plausible explanation for this discrepancy is that 
lipolysis-derived FA were redirected to TG synthesis rather than UCP1 activation16. In support of 
this, we found elevated levels of CD36 and LPL, to promote the reuptake of released FAs into the 
cell, and 2 and 1.7-fold increases in glycerol and palmitate incorporation into lipids, respectively. 
The recycling of lipolysis-derived glycerol is facilitated by the increased expression of GyK. 
However, the majority of the glycerol used for TG esterification is derived from the diet-induced 
increase in PEPCK content60. The drive to store FAs as TG is likely an adaptive response, in vivo, 
to suppressed levels of lipolysis and UCP1 activity and the overabundance of dietary substrate. 
Acute stimulation with a β-agonist was clearly not enough to override this. However, it is 
intriguing to consider whether chronic stimulation, following the consumption of a HFD, could 
reverse these effects and re-brown the whitened brown fat16. In this context, our second and third 
hypotheses are confirmed; FA and glucose are processed and stored as TAG in the BAT of HF-
fed animals. However, contrary to our hypotheses, these mechanisms do not serve to fuel BAT 
thermogenesis.  
The concept of TG re-esterification was demonstrated recently by Sepa-Kishi et al in the 
beige fat of cold-acclimated animals16. In their study, the elevated rate of TG synthesis was met 
by an accelerated rate of lipolysis, producing an energy-consuming cycle that likely contributed to 
decrease WAT mass and conferred a multilocular appearance to the white adipocytes16. In our 
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study we found a similar increase in TG synthesis, but no change in lipolysis.  In this context, the 
rate of TG turnover was reduced, favouring the growth of the lipid droplets in the brown 
adipocytes. Taken together, the attenuations in Oligo and Iso-stimulated palmitate oxidation 
indicate that UCP1 activity and DIT are compromised in the BAT under conditions of DIO, making 
the HF animals more metabolically efficient68 and prone to increasing their fat mass.  
Another factor contributing to the reduction in palmitate oxidation is respiratory chain 
dysfunction. Under basal conditions, proton flow from the mitochondrial intermembrane space to 
the matrix is partitioned through UCP1 and ATP Synthase57. Therefore, when ATP Synthase is 
inhibited with Oligo, the proton flux through UCP1 is increased, producing a burst in UCP1-
mediated palmitate oxidation. This response was observed in the BAT of the SC animals and is 
indicative of a recruitable thermogenic reserve in this tissue. In contrast, when brown adipocytes 
from HF animals were incubated with Oligo, palmitate oxidation did not change. This suggests 
that oxidation is already exclusively mediated by UCP1 and devoid of ATP Synthase activity. 
Based on these findings, we can conclude that HF-feeding suppresses respiratory chain activity 
and oxidative phosphorylation in brown adipocytes. Diet-induced alterations to mitochondrial 
function have been reported by other researchers, including Shimizu et al., who found that obesity-
induced hypoxia in the BAT of mice promotes the formation of reactive oxygen species and the 
onset of mitochondrial dysfunction71.  Furthermore, it is plausible to consider that the reduction in 
ATP Synthase activity seen in brown adipocytes from HFD animals is a consequence of mitophagy 
and lower mitochondrial content71, which explains the shift to glycolysis in these cells. However, 
this warrants further investigation. 
Similar to palmitate oxidation, glucose oxidation was also consistently lower in the BAT 
of the HF animals under all incubation conditions (Basal, Iso, Oligo, Iso+Oligo), reaching 
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significance with Oligo. We measured GLUT1 and GLUT4 protein expression to eliminate 
transport as a limiting factor for glucose metabolism and found that GLUT1 content increased 
24.9-fold and GLUT4 did not significantly change. However, the measure of GLUT4 did not 
differentiate between cytosolic and membrane-bound GLUT4 and was, therefore, not a good 
representative measure of insulin-stimulated glucose uptake5. We therefore ran a glucose uptake 
assay to measure basal and insulin-stimulated glucose import. When stimulated with insulin, there 
was an expected increase in glucose uptake in the brown adipocytes of SC animals, however, there 
was no change in the brown adipocytes of HF animals. Furthermore, when comparing the two 
groups to each other, there was a 78% reduction in insulin-stimulated glucose uptake in the HF 
animals. Similar findings were reported by Lapa et al. who found that insulin-stimulated glucose 
uptake was severely impaired in a rat model of Type II diabetes83.  Therefore, it is evident that 
chronic HF-feeding causes the BAT to develop IR. Under basal conditions, this difference between 
the two groups was not evident. This is likely due to the overexpression of GLUT1 in this tissue, 
which compensated for the reduction in basal GLUT4-mediated glucose uptake. However, this 
mechanism is evidently limited in its capacity to compensate for the impairment in insulin-
stimulated glucose uptake, as was demonstrated in the brown adipocytes from the HF animals.  
It was then important for us to consider the fate of the glucose being imported under basal 
conditions. Because glucose oxidation is suppressed, we hypothesized that this glucose was 
entering the glycolytic pathway and being converted to lactate, rather than pyruvate46. 
Accordingly, we demonstrated a 2.7-fold increase in lactate production in the BAT of the HF 
animals, confirming our hypothesis. Hypoxia is known to develop in the brown adipocytes of HF-
fed animals71. This is compatible with a shift to anaerobic glucose metabolism and an enhanced 
production of lactate46. Glycolysis-derived lactate is used as a substrate for glyceroneogenesis84, 
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further promoting the synthesis of TG and the growth of intracellular lipid droplets in the brown 
adipocytes  
In conclusion, although there is an increase in the content of oxidative proteins, palmitate 
and glucose oxidation are significantly reduced in the BAT of HF-fed animals. Instead, FAs are 
used for TG synthesis and storage. The deposition of lipids in this tissue is further promoted by 
the diet-induced attenuation of lipolysis. The subsequent hypertrophy of these adipocytes confers 
a more unilocular appearance to the cells.  Furthermore, this tissue develops insulin resistance and 
loses its ability to contribute to glucose clearance from the circulation, which exacerbates the 
metabolic complications imposed by the diet. Together, these functional and structural adaptations 
make the BAT appear and function more like WAT. The process of conversion is known as 
whitening70. These adaptations are compatible with the increase in fat mass and enhanced capacity 
to gain weight. Understanding the molecular mechanisms that are impacted in the BAT under 
conditions of DIO provides us with metabolic targets for therapeutic management of obesity and 
insulin resistance.  
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Fig. 15: Despite the increases in carnitine palmitoyltransferase-1B (CPT1B) and Uncoupling 
protein-1 (UCP1) in the brown adipose tissue (BAT) of high-fat (HF)-fed animals, relative to 
controls, mitochondrial uncoupling is impaired. Instead, fatty acids (FAs) are being diverted to 
triacylglycerol (TG) synthesis in the cell. TG formation is supported by the increases in glycerol 
kinase (GyK) and phosphoenolpyruvate carboxykinase (PEPCK) contents, which provide the 
glycerol-3-phosphate (G3P) necessary for FA esterification, and FA uptake which is supported by 
the increased expression of cluster differentiation 36 (CD36) and lipoprotein lipase (LPL). 
Norephinephrine (NE)-stimulated lipolysis is limited due to the reduction of catecholamine 
synthesis and adipose triglyceride lipase (ATGL) content. This can contribute to the reduced 
activation of UCP1. Basal glucose uptake is preserved due to the increase in glucose transporter 1 
(GLUT1) protein content. The glucose that is imported in to the cell is diverted to glycolysis and 
lactate production is enhanced. Accordingly, there is a reduction in glucose oxidation. Insulin-
stimulated glucose uptake is suppressed, indicating the development of insulin resistance in BAT 
under conditions of HF-feeding.  GLUT4, glucose transporter isoform 4; INS, insulin receptor;  
pHSL,  phosphorylated HSL; β-AdR, β-adrenergic receptor; LD, lipid droplet; DAG, 
diacylglycerol; MAG, monoacylglycerol; GlycNG, glyceroneogenesis; Pyr, pyruvate.  X indicates 
suppression of a pathway. Arrows indicate flow through a pathway. 
 
59 
 
6. Future Directions 
 
 In this study, we provide evidence that DIT is suppressed under conditions of DIO.   
However, little is known regarding the temporal progression of the involved metabolic adaptations 
in BAT. In this context, a future direction for this research is to measure diet-induced alterations 
in BAT mitochondrial uncoupling and substrate metabolism over the course of a HFD. So et al. 
reported a transient increase in whole-body energy expenditure that occurred in the first few days        
of HF feeding in rats, but was turned off as HF feeding continued69. Therefore, a time-dependent 
analysis of BAT thermogenesis particularly at early stages of HF-feeding may reveal novel 
information regarding the molecular mechanisms that lead to the inability of BAT to sustain a 
thermogenic response in the face of energy surplus.   
 Another potential future direction is studying BAT function under alternative dietary 
conditions. The diet we provided our HF animals with was high in fat and sucrose. However, it is 
relevant to consider whether a ketogenic diet would generate a different result with respect to BAT 
adaptations. Srivastava et al. fed mice a ketogenic diet and found that UCP1 content was enhanced 
in the BAT85. This was accompanied by an increase in ETC proteins. Therefore, I propose 
investigating BAT mitochondrial uncoupling under conditions of ketogenic feeding to determine 
whether substrate oxidation is altered under such conditions. Given the HF content of the diet, it 
is also important to investigate whether glucose disposal through UCP1-mediated uncoupling is 
enhanced in BAT by feeding a ketogenic diet.   
 These proposed future directions carry great impact for the understanding BAT function 
under different dietary conditions and is of tremendous importance for the development of 
therapeutic tools for the management of obesity and related metabolic disorders. 
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Appendix 
 
A. Adipocyte Isolation 
1. Extract iBAT and aBAT and carefully trim away any muscle, connective tissue, 
and white fat. Combine iBAT and aBAT to maximize the yield of brown 
adipocytes.  
2. Incubate the tissues in a 50 ml falcon tube containing Krebs-Ringer Buffer 
(0.154 M NaCl, 0.154 M KCl, 0.11 M CaCl2, 0.154 M MgSO4, 0.154 M 
KH2PO4, 0.154 M NaHCO3, pH 7.4) with 5.5 mM glucose, 30 mM HEPES 
(KRBH) and 4% BSA, supplemented with collagenase (0.83 mg/ml) at 37°C 
under orbital agitation (120 orbital strokes/ min) for 5 min.  
3. Vortex the combined tissues for 5 seconds 
4. Filter the tissues and discard the filtrate 
5. Finely mince the remaining tissues with surgical scissors and incubate them in 
fresh KRBH-4% BSA containing collagenase (0.83 mg/ml) at 37°C under 
orbital agitation (120 orbital strokes/ min) for about 20-30 min  
6. Strain the digested tissue using a nylon mesh and isolate cells 
7. Transfer the isolated cells to a 50 ml falcon tube 
8. Add 5 ml of KRB to dilute the concentration of the collagenase and reduce its 
activity 
9. Centrifuge the cells at 1000 RPM for 30 sec to allow the adipocytes to float to 
the top of the media 
10. Aspirate the media slowly, leaving only the adipocytes in the falcon tube 
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11. Wash the adipocytes with KRBH and allow the cells to float and settle at the 
top of the media by leaving the falcon tube in the tube rack for 10 min 
12. Repeat the wash and aspiration twice more 
13. Resuspend the cells in KRBH containing 3.5%-FA free BSA (KRBH-3.5% 
BSA) 
14. Count the number of cells present in the falcon tube 
a. Determine lipocrit height by swirling the falcon tube and transferring a 
300 μl aliquot into a centrifuge tube. Centrifuge these cells at 1000 RPM 
for 30 s and measure the lipocrit height using a ruler. 
b. Determine cell diameter by swirling the falcon tube, transferring a 20 μl 
aliquot of adipocytes onto a glass slide and measuring their diameters 
under a light microscope 
c. Determine the number of cells available in the falcon tube by using the 
equation for calculating the volume of a sphere, the volume of media in 
the falcon tube and the lipocrit height in the centrifuge tube  
15. Allocate the appropriate number of cells into each scintillation vial for 
subsequent assays 
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B. Free Glycerol Determination as a Measure of Lipolysis using the 
Sigma Free Glycerol Determination Kit (Cat. # FG0100-1KT) 
1. Thaw the frozen media samples to be analyzed for free glycerol 
2. Reconstitute the free glycerol reagent in 40 ml of water in the amber bottle 
containing the reagent 
3. Stopper the vial and mix by gentle inversion 
4. Store the reconstituted reagent in the dark  
5. Add 10 μl of water, Glycerol Standard and sample to each pre-labelled cuvette 
6. Pipette 800μl of the reconstituted glycerol reagent into each cuvette 
7. Mix the sample and reagent by gently vortexing the cuvette 
8. Incubate the cuvettes at 37°C for 5 min 
9. Measure the absorbance (A) of the standard and samples on a 
spectrophotometer at 540nm. 
10. Calculate the concentration of free glycerol in each sample using the equation: 
                                                     = (ASAMPLE-ABLANK)      x Concentration of Standard 
           (ASTANDARD-ABLANK) 
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C. Glucose and Palmitate Oxidation  
1. Isolate and pipette 5x105 adipocytes into scintillation vials containing 1.5 ml of 
KRBH-3.5% BSA with 0.2 μCi/ml D-[U-14C] glucose and 5.5 mM non-labeled 
D-glucose KRBH-3.5% BSA or KRBH-3.5% BSA containing [1-14C] palmitic 
acid and 200 μM non-labelled palmitate. 
a. To examine the effect of lipolysis on glucose/palmitate oxidation, add 
100 nM of isoproterenol (Iso) 
b. To examine the differences between coupled and uncoupled respiration 
in these adipocytes, add 100 μM of oligomycin (Oligo).  
i. Following the addition of Oligo, swirl the scintillation vial and 
incubate it at room temperature for 15 min prior to the incubation 
with/without Iso 
2. Carefully place a cap-less Eppendorf containing a loosely folded piece of filter 
paper in the scintillation vial 
3. Seal the vial with a rubber cap 
4. Incubate the scintillation vials for 1 h at 37°C with gentle agitation (80 orbital 
strokes/min). 
5. Following the 1 h incubation period, use a syringe to soak the filter paper in the 
centered well with 200 μl of phenethylamine:methanol (1:1, vol:vol). This filter 
paper will collect 14CO2  
6. Following this, acidify the media using 5 N H2SO4 to release 14CO2 from the 
adipocytes and media 
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7. Incubate the vials at 37°C for 1 h with gentle agitation (80 orbital strokes/min) 
for the collection of 14CO2 
8. Remove the filter paper from the centered well and place it into a separate 
scintillation vial containing 5 ml of scintillation fluid 
9. Count for radioactivity 
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D. Glucose Uptake Assay 
1. Isolate and pipette approximately 4x105 cells per plastic vial 
2. Incubate these cells for 1 h at room temperature with gentle agitation (80 orbital 
strokes/min) 
3. 20 min prior to the end of the incubation, add 100 nM of insulin to the insulin-
treated tubes 
4. Add KRBH-1% BSA containing 0.5 mM 2-deoxy-D-glucose and 0.5 μCi of 2-
[1,2-3H]deoxy-D-glucose to the cells for 3 min  
5. Terminate the incubations  by adding 10 μl of 1.5 mM cytochalasin B to the 
cells  
6. Take 240 μl aliquots of the cell suspensions and transfer them into plastic 
microtubes already containing 125 μl of di-“isononyl” phthalate 
7. Centrifuge the tubes for 30 sec (6000 x g) to separate the adipocytes from the 
radioactive incubation medium 
8. Using a sharp scalpel or box-cutter, cut through the oil phase of the tube that 
now sits between the medium and the adipocyte suspension 
9. Transfer the portion of the tube containing the adipocytes to a scintillation vial 
containing 5 ml of scintillation fluid 
10. Count for radioactivity 
11. Total count must be adjusted for non-specific transport. Measure non-specific 
transport by having two additional plastic tubes with the adipocyte suspension. 
Instead of adding the radioactive medium first, add cytochalasin B. 
12. Subtract non-specific counts from all other counts 
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E. Glycerol Incorporation into Lipids  
1. Isolate and pipette 5x105 cells into scintillation vials containing 1.5 ml of  
KRBH-3.5% BSA containing 0.2 μCi/ml of [14C(U)] glycerol 
2. Seal the vials with rubber caps and incubate for 1 h at 37°C with gentle agitation 
(80 orbital strokes/min) 
3. Remove the rubber caps and add 5 ml of Dole's Reagent 
a. Dole’s Reagent: 40:10:1 (isopropanol:hepane: 0.5 M H2SO4) 
4. Tightly seal the scintillation vial with a cap and vortex for 1 min 
5. Uncap the scintillation vial and add 3 ml of ddH2O and heptane, in sequence 
6. Tightly seal the scintillation vial again and vortex for 1 min 
7. Let the scintillation vial sit for a minimum of 20 min to allow the phases to 
separate 
8. Extract 1 ml of the top heptane phase and place in a separate, pre-weighed 
scintillation vial 
9. Allow the scintillation vial to dry overnight in a laminar fume hood 
10. Weigh the dried scintillation vial the next day to obtain a lipid weight 
measurement 
11. Add 5 ml of scintillation fluid and count for radioactivity 
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F. Lactate Determination using the Biovision Lactate 
Colorimetric/Fluorimetric Assay Kit (Cat. # K607-100) 
1. Thaw the frozen media samples to be analyzed for lactate production 
2. Rinse 10-kDa molecular weight spin filters in 2 ml Eppendorf tubes using 
ddH2O   
3. Add ddH2O to spin filters and centrifuge at 13, 000 RPM for 5 min 
4. Discard the ddH2O from the filters and allow them to dry 
5. Add 100 μl of the sample to the filter and spin at 13, 000 RPM for 5 min at 4°C  
6. Following deproteination of the sample, remove the filter and extract the sample 
from the bottom of the Eppendorf. 
7. Using the Lactate Assay Kit, mix 990 μl of the Lactate Assay Buffer with 10 μl 
of the Lactate Standard to produce the Assay Standard 
8. Load 2, 4, 6, 8 and 10 μl of the Assay Standard into a 96-well plate and bring 
total volume to 50 μl with Lactate Assay buffer. 
9. Load 2-50 μl of sample and bring total volume to 50μl with Lactate Assay 
Buffer 
 Note: In order to determine the optimal quantity of sample to load, a 
pilot run prior to the assay is recommended using varying volumes of 
sample 
10. Add 46 μl of Lactate Assay Buffer, 2 μl of resuspended Lactate Enzyme and 2 
μl of the Lactate Probe per well  
11. Mix reaction mixes well and incubate the 96-well plate for 30 min in the dark 
12. Read the plate at 570nm in a plate reader. 
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G. Palmitate Incorporation into Lipids 
1. Palmitate Incorporation into Lipids 
1. Isolate and pipette 5x105 cells into scintillation vials containing 1.5 ml of  
KRBH-3.5% BSA containing 0.2 μCi/ml of [1-14C] palmitate and 200 μM of non-
labelled palmitate 
2. Seal the vials with rubber caps, gasify for 15 seconds with carbogen gas and 
incubate for 1 h at 37°C with gentle agitation (80 orbital strokes/min) 
3. Following the 1 h, transfer 2 ml of the adipocyte suspension and radioactive 
incubation medium into 2 ml Eppendorf tubes. 
4. Centrifuge the samples at 3000 x g for 1 min  
5. Discard the radioactive medium and wash the cells with 1 ml of PBS 
6. Centrifuge the samples at 3000 x g for 1 min 
7. Repeat steps 5-6 twice more 
8. After the third wash, discard the PBS 
9. Freeze the adipocytes at -80°C until lipid extraction 
2. Lipid Extraction using Folch’s Method80 
1. Take samples out of the -80°C freezer 
2. Resuspend cells in 600 μl of cholorform:methanol (2:1 vol:vol) 
3. Vortex the cells for 30 s 
4. Spin the samples at 3000 x g for 5 min at 4°C 
5. Transfer 300 μl of the upper cholorform phase into a new Eppendorf tube 
6. Allow the tubes to evaporate under nitrogen gas overnight 
7. Resuspend in 50 μl of chloroform:methanol (2:1, vol:vol) 
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3. Thin Layer Chromatography (TLC) 
1. On a Whatman TLC plate, using a pencil, draw a line 2 cm from the bottom of the 
plate 
2. Load 4 μl of TAG standard (triolein) and 4 μl of sample along this line 
3. Using a TLC unit, add 200 ml of your hexane:diethyl ether:acetic acid (70:30:1, 
vol:vol:vol) mobile phase to the bottom of the unit 
4. Place the plate loaded with your samples into the TLC unit 
5. Allow the mobile phase to run up ~80% of the plate 
6. Remove the plate from the unit and allow both to air dry for 10 min 
7. Place the plate back into the TLC unit and add iodine. The iodine vapours will allow 
for visualization of the spots corresponding to the TAG. 
8. Once the spots are visible, remove the plate from the unit and scrape off the spots 
that are aligned with the TAG standard  
9. Add the scraped residue into a scintillation vial containing 5 ml of scintillation fluid 
10. Count for radioactivity 
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H. Measuring Gene Expression in BAT using PCR 
1. RNA Extraction using TRIzolTM 
1. Sterilize work environment and consumables  
2. Transfer 50 mg of tissue into 2 ml tube containing 1 ml of TRIzol 
3. Using a mechanical homogenizer, homogenize the samples 
4. Incubate the samples for 5 min at room temperature to allow for the dissociation 
of the nucleoproteins complex. 
5. Add 200 μl of chloroform to each tube 
6. Vortex each tube vigorously for 15 sec 
7. Incubate the samples for 2-3 mins at room temperature 
8. Centrifuge the samples at 13, 000 RPM for 15 mins at 4°C  
2. RNA Isolation 
1. Extract the aqueous (top) phase and avoid the other two phases.  
2. Move the aqueous phase into a new, sterile, 1.5 ml Eppendorf tube 
3. Add 500 μl of 100% isopropanol to the aqueous phase and mix by inverting the 
tube several times 
4. Incubate the samples at room temperature for 10 min 
5. Centrifuge the samples at 13, 000 RPM for 20 min at 4°C. 
6. Following centrifugation, a pellet should be visible at the bottom of the tube 
7. Discard the supranatant and wash the pellet with 1 ml of 75% ethanol. 
8. Centrifuge the tubes 13, 000 RPM for 20 min at 4°C. 
9. Repeat steps 14-16 to perform a second wash of the pellet 
10. Discard the supranatant. 
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11. Air dry the pellet for 5-10 min 
3. RNA Resuspension  
1. Resuspend the pellet in 20 μl of sterile ddH2O by pipetting in and out several 
times 
2. Assess the concentration and quality of the RNA sample by Nanodrop 
3. Proceed to cDNA synthesis or store samples at -80°C until use 
4. cDNA Synthesis using ABM EasyScriptTM Reverse Transcriptase cDNA 
Synthesis kit 
1. Thaw RNA samples and reagents on ice 
2. Add 2 μg of each RNA sample to sterile tubes 
3. Bring total volume to 12.5 μl with ddH2O 
4. Add 1 μl of random primers and 1 μl of dNTP mix to each sample 
5. Centrifuge briefly 
6. Incubate samples at 65°C for 5 min 
7. Incubate samples on ice for one min 
8. Centrifuge briefly 
9. Make a master mix containing 4 μl of 5X RT buffer, 0.5 μl of RNAse OFF 
Ribonuclease Inhibitor and 1 μl of OneScript mix, per sample 
10. Add 5.5 μl into each tube 
11. Mix components well and collect with centrifuge 
12. Incubate samples at 25°C for 10 min 
13. Perform cDNA synthesis by incubating the tube for 50 min at 42°C 
14. Stop the reaction by heating the samples at 85°C for 5 min 
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15. Incubate on ice. 
16. Proceed to PCR or store cDNA samples at -20°C.  
5. PCR 
1. Thaw cDNA samples 
2. In a 96-well plate, load 10 ng of cDNA per well. 
3. To each sample, add 0.4 μl of the primer of interest, 5.6 μl of ddH2O and 10 μl 
of Brightgreen 2x qPCR Mastermix 
4. Centrifuge the plate at 2000 RPM for 5 min at 4°C 
5. Perform qPCR analysis by using the following amplification conditions:  
 95°C (10 min); 40 cycles of 95°C (15 s), 65°C (1 min); a 0.5°C step-
wise increment from 65°C to 95°C. 
6. Normalize the results to the control gene β-acting and calculate fold change 
using the ∆∆Ct method82. 
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I. Western Blotting: Protein Extraction 
1. Following extraction, tissue is immediately frozen in liquid nitrogen and stored 
at -80°C until homogenization 
2. Move 50 mg of BAT into 2 ml Eppendorf tubes already containing 200 μl of 
lysis buffer (25 mM Tris-HCl, 25 mM NaCl (pH 7.4), 1 mM MgCl2, 2.7 mM 
KCl, 1% Triton-X and protease and phosphatase inhibitors) 
3. Using a mechanical homogenizer, homogenize the tissue sample 
4. Sonicate sample 3X for 3 seconds each time at 40% amplitude 
5. Following this, centrifuge the samples at 13, 000 RPM at 4°C for 10 min 
6. Remove the samples from the centrifuge and extract the protein lysate from the 
Eppendorf, avoiding the pellet that formed at the bottom of the tube 
7. Transfer the lysate into a separate, clean Eppendorf 
8. Extract an aliquot for protein quantification using the Bradford method. 
9. Samples can be used immediately for Western Blotting or can be stored at -
80°C and used at a later date. 
1. Lysate Preparation with Laemli 
1. Prepare 50μl of 2-mercaptoethanol in 950μl of 2X Lameli buffer. 
2. Dilute samples 1:1 with Laemli buffer 
3. Boil lysate/laemli at 95°C for 5 mins 
4. Centrifuge lysate/laemli briefly 
5. Proceed to Western blot 
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J. Western Blotting 
1. Western Blot Gel Components 
1.1. 1.5 M Tris-HCl, pH 8.8 
27.3 g of tris Base 
80 ml of deionized water 
Adjust to pH 8.8 with 6N HCl  
Bring total volume to 150 ml with deiodinized water 
1.2. 0.5 M Tris-HCl 
6 g of Tris base 
60 ml of deiodinized water 
Adjust to pH 6.8 with 6N HCl 
Bring total volume to 100 ml with ddH2O water 
1.3. 10X Electrode (Running) buffer, pH 8.3 (1 L) 
30.3 g of Tris base 
144 g of Glycine 
10 g of SDS 
Dissolve and bring the total volume to 1L with ddH2O 
1.4. 10% APS 
Dissolve 100 mg of ammonium persulfate in 1 ml of ddH2O.  
Make APS fresh each time 
2. Western Blot Gel Formulations 
2.1. Resolving Gel 
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1. Prepare the monomer solution by mixing appropriate quantities of the following 
reagents: 
% Gel ddH2O (ml) 30% 
Acrylamide/Bis 
(ml) 
Gel buffer (ml) 
1.5M Tris-HCl, 
pH 8.8 
10% (w/v) SDS 
(ml) 
 
 2 Gels 4 Gels 2 Gels 4 Gels 2 Gels 4 Gels 2 Gels 4 Gels 
7% 7% 8.61 17.23 3.97 7.93 4.25 8.5 0.17 
8% 8.05 16.1 4.53 9.06 4.25 8.5 0.17 0.34 
10% 6.91 13.82 5.67 11.34 4.25 8.5 0.17 0.34 
12% 5.78 11.56 6.8 13.6 4.25 8.5 0.17 0.34 
 
2. APS and TEMED are added last. For one gel, add 100 μl of 10% APS and 10 
μl of TEMED. Mix well and add the gel preparation into the plate 
2.2. Stacking Gel (4% Gel) 
ddH2O (ml) 30% 
Acrylamide/Bis 
(ml) 
Gel buffer (ml) 
pH 6.8 
10% (w/v) SDS 
(ml) 
2 Gels 4 Gels 2 Gels 4 Gels 2 Gels 4 Gels 2 Gels 4 Gels 
3.94 7.88 0.87 1.73 1.63 3.25 0.065 0.13 
 
3. Similar to the preparation for the resolving gel, only add 10% APS and TEMED 
following the mixture of the other components  
4. For 1 gel add 50 μl of 10% APS and 5 μl of TEMED  
5. Mix well and add to the top of the Resolving Gel in the plates   
6. After filling the plates with the stacking gel, gently insert the well combs  
7. Allow the gels to polymerize for 15-20 minutes 
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3. Loading the Gel 
1. Once the gels have polymerized, place the plates into running clamps and insert 
the clamps into a running apparatus 
2. Fill the running apparatus with 1X Running Buffer 
3. Gently remove the well combs 
4. Load 25 μg of protein into each well 
5. Once all wells are loaded, run the gel at 110V for 2 h 
4. Transfer 
4.1. Transfer Buffers  
4.1.1. 10X Transfer Buffer 
   25 mM Tris base 
   192 mM Glycine 
Dissolve in make total volume to 1 L of ddH2O 
4.1.2. 1X Transfer Buffer (1 L) 
700 ml of ddH2O 
200 ml of methanol 
100 ml of 10X transfer buffer 
5.2. PVDF Membrane Activation 
1. Place pre-cut PVDF membranes into a container  
2. Submerge the membranes with 100% methanol 
3. Leave membranes in methanol for 30 s 
4. Discard the methanol and quickly rinse the membranes with ddH2O before 
submerging them for 2 min in ddH2O 
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5. Discard the ddH2O and pour 1X Transfer Buffer over the membranes 
6. Allow membranes to equilibrate for 10 minutes 
5.3. Wet Transfer Protocol 
1. Prepare a casserole dish with transfer cassettes, fiber pads and pre-cut filter 
paper 
2. Add enough 1X Transfer buffer to the casserole dish to cover the bottom and to 
soak the filter paper and fiber pads 
3. Assemble the bottom of the cassette by adding a fiber pad, followed by 2, pre-
soaked filter papers 
4. Remove one set of plates containing a gel from the running apparatus 
5. Carefully separate the two plates using a flat pick and transfer the gel onto the 
filter paper in the transfer cassette 
6. Once the gel is centered on the filter paper, carefully place a membrane on top 
of the gel 
7. Roll the top of the membrane to remove any bubbles from in between the 
membrane and the gel 
8. Place a filter paper on top of the membrane and roll it again 
9. Place a second filter paper on top of the previous one and roll it a final time  
10. Add a pre-soaked fiber pad to the top of the second filter paper and clamp the 
cassette shut. 
11. Place the casette in the transfer apparatus 
12. Close the transfer apparatus and incubate it at 4°C 
13. Set the transfer to 120V for 2 h 
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5. Probing the Membrane 
5.1. Buffers 
5.1.1. 10X Wash Buffer (1 L) 
60.57 g of Tris base 
87.66 g of NaCl 
5.1.2. 1X Wash Buffer (1 L) 
Dilute to 1X using ddH2O 
Add 500 μl of Tween 
Add 500 μl of NP40 
5.1.3. Blocking Buffer (3% BSA) 
Dissolve 1.5 g of crude BSA in 50 ml of 1X Wash buffer 
5.2. Blocking the Membrane 
1. After the transfer is complete, prepare containers with 8 ml of blocking buffer 
in each 
2. Remove the membrane from the transfer apparatus and place it in one of the 
containers immediately  
3. Shake for 1 h 
5.3. Incubation with Primary Antibody 
4. Dilute the antibody of interest in blocking buffer 
 Note: dilutions vary based on the affinity of the antibody for the protein 
and the abundance of the protein in the lysate 
5. Discard the blocking buffer that was shaking over the membrane and 
immediately add the primary antibody preparation 
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6. Incubate the membrane in this antibody for 2 h at room temperature with gentle 
shaking 
7. After two hours, discard the primary antibody dilution 
8. Wash the membrane with 1X wash buffer 5x10 min 
5.4. Incubation with Secondary Antibody 
9. Dilute the secondary antibody in blocking buffer 
10. Discard the wash buffer 
11. Immediately add the secondary antibody 
12. Incubate for 1 h at room temperature with gentle shaking 
13. After 1 h, wash the membrane with 1X wash buffer 5x10 min 
5.5. Developing the Membrane 
14. Discard the secondary antibody and allow any excess liquid to run out of the 
containers  
15. Add Luminata Western HRP Chemiluminescent Substrate (Luminata) to the 
membranes and shake gently by hand for 2 min 
16. Discard the Luminata  
17. Remove the membranes from the containers and place them in film 
development cassettes 
18. In a dark room, expose film to the membranes for varying amounts of times to 
obtain different exposures 
19. After the desired exposure time passes, remove the film from the development 
cassettes 
20. Dip the film in Developer Fluid until bands begin to appear 
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21. After the bands become visible, immediately wash the film in water and fix in 
Fixer Fluid until film loses opaque blotches. 
22. When film is completely transparent, wash off residual Fixer Fluid with water 
